mitomycin has been researched along with Neoplasms in 287 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Erythropoietin may be lowered by cancer itself or because of chemoradiotherapy." | 6.76 | Chronic anemia due to mitomycin C is drug dose-dependent, normocytic, progressive, related to erythropoietin levels and quantitatively predictable: implications for radiochemotherapy. ( Cartei, F; Cartei, G; Colombrino, E; Fiorica, F; Giraldi, T; Micucci, M; Plebani, M; Sanzari, MC; Zustovich, F, 2011) |
| " Results of our preclinical and clinical studies including a randomized prospective phase III trial have validated the concept that enhanced drug delivery can significantly improve the treatment efficacy of intravesical mitomycin C therapy of superficial bladder cancer." | 5.10 | Clinical aspects of drug delivery to tumors. ( Au, JL; Jang, SH; Wientjes, MG, 2002) |
| " One patient with aggressive fibromatosis was treated with TNF alone (200 micrograms/m2, days 1-5 every third week) and 10 patients (four colon cancer, four head and neck cancer; one melanoma; one sarcoma) received mitomycin C (15 mg/m2, day 1) followed by TNF (60-180 micrograms/m2, days 1-3) every sixth week." | 5.08 | Tumor necrosis factor administration is associated with increased endogenous production of M-CSF and G-CSF but not GM-CSF in human cancer patients. ( Gooding, W; Kirkwood, JM; Logan, TF; Shadduck, RK, 1996) |
| "Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| " Specifically, pharmacological inhibition of WRN helicase activity in human cells defective in the Fanconi anemia (FA) pathway of interstrand cross-link (ICL) repair are sensitized to the DNA cross-linking agent and chemotherapy drug mitomycin C (MMC) by the WRN helicase inhibitor NSC 617145." | 3.79 | Targeting an Achilles' heel of cancer with a WRN helicase inhibitor. ( Aggarwal, M; Banerjee, T; Brosh, RM; Sommers, JA, 2013) |
| " Results of treatment of B16 melanoma and Lewis lung carcinoma with 3,4-dihydroxybenzohydroxamic acid are used to demonstrate this definition." | 3.66 | Drug activity and therapeutic synergism in cancer treatment. ( Campbell, ED; Carter, WH; Stablein, DM; Wampler, GL, 1982) |
| "Virogenic cell cultures of a hamster ependymoma originally produced by Simian Virus 40 were treated with proflavine, hydrogen peroxide, or mitomycin C." | 3.64 | VIROGENIC HAMSTER TUMOR CELLS: INDUCTION OF VIRUS SYNTHESIS. ( GERBER, P, 1964) |
| "8 mg/kg in combination with RT treatment is safe, with a high rate of tumor control." | 3.30 | Pegylated Liposomal Mitomycin C Lipidic Prodrug in Combination With External Beam Radiation Therapy in Patients With Advanced Cancer: A Phase 1B Study. ( Amitay, Y; Corn, B; Gabizon, A; Levy, A; Ohana, P; Pfeffer, R; Purim, O; Sapir, E; Wygoda, M, 2023) |
| " We screened cancer patients' tumors for FA functional defects then aimed to establish the safety/feasibility of administering PARP inhibitors as monotherapy and combined with a DNA-breaking agent." | 2.82 | Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. ( Bekaii-Saab, T; Chen, A; Duan, W; Ji, J; Lustberg, M; Marshall, J; Rose, J; Schaaf, LJ; Shilo, K; Thurmond, J; Timmers, C; Villalona-Calero, MA; Westman, JA; Xiaobai, L; Zhao, W, 2016) |
| "Mitomycin C (MMC) has potent cytotoxicity but cumulative toxicity limits widespread use." | 2.80 | Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients. ( Amitay, Y; Berger, R; Gabizon, AA; Golan, T; Grenader, T; La-Beck, NM; Ohana, P; Shmeeda, H; Tahover, E, 2015) |
| "Erythropoietin may be lowered by cancer itself or because of chemoradiotherapy." | 2.76 | Chronic anemia due to mitomycin C is drug dose-dependent, normocytic, progressive, related to erythropoietin levels and quantitatively predictable: implications for radiochemotherapy. ( Cartei, F; Cartei, G; Colombrino, E; Fiorica, F; Giraldi, T; Micucci, M; Plebani, M; Sanzari, MC; Zustovich, F, 2011) |
| "Irinotecan was escalated in 25 mg/m(2) increments." | 2.74 | Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies. ( Drengler, R; Duan, W; Kolesar, JM; Kuhn, J; Otterson, G; Schaaf, LJ; Shapiro, C; Villalona-Calero, MA; Xu, Y, 2009) |
| " In conclusion, capecitabine can safely be combined with docetaxel (40 mg m(-2)) and mitomycin C (4 mg m(-2))." | 2.73 | Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial. ( Ernst, T; Gnad-Vogt, U; Hochhaus, A; Hofheinz, RD; Kripp, M; Lukan, N; Merx, K; Schultheis, B, 2007) |
| "54 patients with advanced malignancy refractory to chemotherapy were studied to evaluate efficacy and toxicity of continuous infusion of 5-fluorouracil (5FU) given for 3 weeks." | 2.69 | [Dose-intensive chemotherapy with continuous infusion 5-fluorouracil]. ( Berger, R; Brenner, H; Ghodsizade, E; Katz, A; Rath, P; Tichler, T, 1999) |
| "BMS-181174 has anti-cancer activity but, because of its toxicity, particularly pneumonitis and thrombophlebitis, no phase II studies are planned." | 2.69 | Phase I study of the mitomycin C analogue BMS-181174. ( Ganesan, TS; Green, JA; Harris, AL; LaCreta, FP; Macaulay, VM; McKinley, L; O'Byrne, KJ; Philip, PA; Talbot, DC; Winograd, B, 1998) |
| "One patient with metastatic colon cancer had a partial response of liver metastases." | 2.69 | Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors. ( de Boer-Dennert, M; Planting, AS; Schellens, JH; Stoter, G; van der Burg, ME; Verweij, J; Winograd, B, 1999) |
| "Patients with refractory solid tumors (n = 51) were treated with a 48-h continuous intravenous infusion of menadione followed by a bolus intravenous dose of mitomycin C at the completion of the menadione infusion." | 2.68 | Phase I study of mitomycin C and menadione in advanced solid tumors. ( Ahn, C; Akman, SA; Doroshow, JH; Leong, LA; Margolin, KA; Morgan, RJ; Raschko, JW; Somlo, G, 1995) |
| " The aim of this phase I study was to determine the toxicity profile and the optimal dosage of KW-2149." | 2.68 | Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149. ( Ardiet, C; Catimel, G; De Bruijn, E; Dirix, L; Dumortier, A; Evene, E; Joossens, E; Koier, I; Provè, A; Schrijvers, D, 1995) |
| "Cancers were typed with both immunohistochemistry and flow cytometry using a panel of antibodies." | 2.67 | Custom-tailored drug immunoconjugates in cancer therapy. ( Oldham, RK, 1991) |
| "The effect of fibrinolytic agents, Tissue Culture Urokinase (TCUK) and Urinary Urokinase (UUK), was investigated in a total of 146 patients with gastric cancer, pulmonary cancer or breast cancer who received various anti-cancer agents, mainly MMC, in combination with the fibrinolytic agents." | 2.65 | [Clinical evaluation of various antineoplastic agents combined with urokinase--a comparison between urokinase from tissue culture (TCUK) and urine-derived urokinase (UUK)]. ( Yamamoto, M, 1982) |
| "This finding was clinically applied to cancer chemotherapy for enhancing drug delivery to tumor tissue selectively." | 2.65 | [Clinical studies on induced hypertension chemotherapy based on functional characteristics of microcirculation of tumor vessels]. ( Sato, H; Wakui, A, 1984) |
| "Mitomycin C was reviewed in this journal 25 years ago and an update of its clinical usefulness is appropriate." | 2.41 | Mitomycin C: a clinical update. ( Bradner, WT, 2001) |
| "Cancer is a common life-threatening disease." | 2.41 | [From cancer prevention to cancer treatment]. ( Shudo, K, 2000) |
| "Hypoxic cells of solid tumors represent a therapeutically resistant population that limits the curability of many solid tumors by x-irradiation and by most chemotherapeutic agents." | 2.39 | Mitomycin C: a prototype bioreductive agent. ( Belcourt, MF; Fischer, JJ; Haffty, B; Hodnick, WF; Rockwell, S; Sartorelli, AC; Tomasz, M, 1994) |
| "Certain anticancer agents form free radical intermediates during enzymatic activation." | 2.38 | Free radicals and anticancer drug resistance: oxygen free radicals in the mechanisms of drug cytotoxicity and resistance by certain tumors. ( Mimnaugh, EG; Sinha, BK, 1990) |
| "The sensitivity of various human tumors xenografted to nude mice has been tested to antitumor agents to establish the system which could select the clinically active drugs." | 2.37 | [Recent advanced studies on mitomycins, antitumor activity and mode of action]. ( Morimoto, M; Taguchi, T, 1987) |
| "In this report the effects of anticancer agents on immune effector cells were analyzed and the possibility about the development of a reliable monitoring procedure for determining a potent treatment protocol was discussed." | 2.36 | [Effect of chemotherapy on anticancer immune effector cells]. ( Saijo, N, 1983) |
| "A crucial element of cancer treatment is radiation therapy that is used to destroy tumors and cancer cells through radiation." | 1.91 | Radiation Therapies in Cancer. ( Ali, SW; Fatima, N; Hameed, A; Jabeen, A; Qazi, AS; Safdar, W; Tariq, MR, 2023) |
| "The generation time of this cancer cell line had a distribution with a long tail and a heritability across generations." | 1.62 | Intrinsic growth heterogeneity of mouse leukemia cells underlies differential susceptibility to a growth-inhibiting anticancer drug. ( Nakaoka, H; Okura, R; Seita, A; Wakamoto, Y, 2021) |
| "RUNX-Walker motif mutations from breast cancers are impaired for DNA damage-inducible PARylation, unveiling a potential mechanism for FA pathway inactivation in cancers." | 1.48 | RUNX Poly(ADP-Ribosyl)ation and BLM Interaction Facilitate the Fanconi Anemia Pathway of DNA Repair. ( Chong, YL; Chuang, LSH; Ito, Y; Kappei, D; Kolinjivadi, AM; Krishnan, V; Sankar, H; Tan, TZ; Tay, LS, 2018) |
| " Nanoparticle-based drug combination has been shown to mitigate the problems encountered by free drug combination therapy." | 1.46 | Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice. ( Chen, K; Cheng, J; Lai, P; Pang, KS; Rauth, AM; Wu, XY; Zhang, RX; Zhang, T, 2017) |
| "Mitomycin C (MMC) is a powerful anti-bacterial, anti-fungal and anti-tumor antibiotic, often active against multidrug resistant cells." | 1.43 | Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity. ( Amitay, Y; Gabizon, A; Ohana, P; Patil, Y; Shmeeda, H, 2016) |
| "To explore in vitro anticancer potential of Aerva lanata L." | 1.39 | In vitro anti cancer activity of ethanol extract fractions of Aerva lanata L. ( Bhanot, A; Noolvi, MN; Sharma, R; Singh, S, 2013) |
| " This pilot study demonstrates the utility of using yeast for screening large matrices of drug combinations, and it provides a means to prioritize drug combination tests in human cells." | 1.39 | A high-throughput yeast assay identifies synergistic drug combinations. ( Brown, GW; Giaever, G; Lee, AY; Nislow, C; Torres, NP, 2013) |
| "In addition, in a mouse colorectal cancer model administration of nanoparticulate SN38 once weekly exhibited greater activity compared to daily or weekly administration of irinotecan." | 1.39 | Preclinical antitumor activity of a nanoparticulate SN38. ( Al-Kasspooles, MF; Decedue, CJ; Henry, D; Howell, J; Niu, F; Roby, KF; Williamson, SK, 2013) |
| "The benefit of cancer chemotherapy based on alkylating agents is limited because of the action of DNA repair enzymes, which mitigate the damage induced by these agents." | 1.39 | Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells. ( Barakat, KH; Bouledrak, K; Cohen, R; Cros-Perrial, E; Dumontet, C; El Sabeh, R; Heinrich-Balard, L; Jordheim, LP; Matera, EL; Perez-Pineiro, R; Tuszynski, J; Wishart, DS, 2013) |
| "and compound 7c exhibit good anticancer activity against ovary (IGR-OV-1), breast (MCF-7) and CNS(SF-295) human cancer cell lines." | 1.36 | Solvent free synthesis, anti-inflammatory and anticancer activity evaluation of tricyclic and tetracyclic benzimidazole derivatives. ( Agrawal, SK; Rani, R; Roy, P; Saxena, AK; Singh, J; Sondhi, SM, 2010) |
| " The dose-response of ethylnitrosourea-induced mutation was found to be very close to that previously established using a pedigree-based approach for ESTR mutation detection." | 1.35 | Single-molecule PCR analysis of germ line mutation induction by anticancer drugs in mice. ( Dubrova, YE; Glen, CD; Smith, AG, 2008) |
| "Chemotherapy can induce anticancer immune responses." | 1.35 | Chemotherapy induces ATP release from tumor cells. ( Kepp, O; Kroemer, G; Martins, I; Métivier, D; Michaud, M; Perfettini, JL; Schlemmer, F; Senovilla, L; Séror, C; Tesniere, A; Zitvogel, L, 2009) |
| "Since the Fanconi anemia-breast cancer associated (FANC-BRCA) DNA damage response network plays a crucial role in protecting cells against ICLs, in the present work we tested this hypothesis by exposing cells to AA and monitoring activation of this network." | 1.35 | Acetaldehyde stimulates FANCD2 monoubiquitination, H2AX phosphorylation, and BRCA1 phosphorylation in human cells in vitro: implications for alcohol-related carcinogenesis. ( Brooks, PJ; Lamerdin, JE; Marietta, C; Thompson, LH, 2009) |
| "Therefore, the fact that tumors do not develop in the majority of the population during their lifetime indicates the existence of other defense system(s)." | 1.35 | Experimental evidence for killing the resistant cells and raising the efficacy and decreasing the toxicity of cytostatics and irradiation by mixtures of the agents of the passive antitumor defense system in the case of various tumor and normal cell lines ( Kulcsár, G, 2009) |
| "Ascites was from gastric cancer (5 cases), colorectal cancer (3 cases), ovarian cancer (3 cases), breast cancer (2 cases) and peritoneal mesothelioma (1 case)." | 1.33 | Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. ( Garcia, J; Garofalo, A; Sugarbaker, PH; Valle, M, 2006) |
| "Therefore, genomic instability generated NCCAs are a key driving force in cancer progression." | 1.33 | Stochastic cancer progression driven by non-clonal chromosome aberrations. ( Bremer, SW; Heng, HH; Liu, G; Reddy, PV; Stevens, JB; Tainsky, MA; Wang, YA; Wu, GS; Ye, CJ; Ye, KJ, 2006) |
| "Mitomycin C is a bioreductive agent that is used clinically for treatment of solid tumors." | 1.33 | Effect of NQO1 induction on the antitumor activity of RH1 in human tumors in vitro and in vivo. ( Begleiter, A; Digby, T; Leith, MK; Thliveris, JA, 2005) |
| "Systemic anticancer chemotherapy is immunosuppressive and mostly induces nonimmunogenic tumor cell death." | 1.33 | Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. ( Aucouturier, P; Casares, N; Chaput, N; Coutant, F; Garrido, C; Ghiringhelli, F; Hamai, A; Hervas-Stubbs, S; Kroemer, G; Métivier, D; Obeid, M; Pequignot, MO; Pichard, E; Pierron, G; Roux, S; Schmitt, E; Tesniere, A; Zitvogel, L, 2005) |
| "Their effectiveness in cancer chemotherapy can be enhanced by delivering to tumors enzymes with improved prodrug reduction kinetics." | 1.33 | New enzyme for reductive cancer chemotherapy, YieF, and its improvement by directed evolution. ( Ackerley, DF; Barak, Y; Contag, CH; Lynch, SV; Matin, A; Thorne, SH, 2006) |
| "The LD50 of pentamidine on cancer cells maintained in vitro is correlated with the endo-exonuclease enzyme activity." | 1.32 | The DNA double-stranded break repair protein endo-exonuclease as a therapeutic target for cancer. ( Alaoui-Jamali, MA; Chow, TY; Griller, D; Yeh, C; Yuen, L, 2004) |
| "Mice bearing sarcoma 180 tumors were used as an in vivo model." | 1.32 | Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin. ( Akaike, T; Fang, J; Greish, K; Maeda, H; Sawa, T, 2004) |
| "Mitomycin C (MMC) is an anticancer drug that requires reductive activation to exert its toxicity." | 1.32 | Role of GRP58 in mitomycin C-induced DNA cross-linking. ( Celli, CM; Jaiswal, AK, 2003) |
| "CT26 (a murine colon cancer cell line syngeneic with BALB/c) and CT26-bearing mice were treated with mitomycin C (MMC) intraperitoneally (i." | 1.32 | Dendritic cells coinjected with tumor cells treated with an anticancer drug to induce tumor rejection. ( Furumoto, K; Imamura, M; Inoue, N; Kan, T; Kondo, K; Yamasaki, S, 2003) |
| " Numerical solutions of the resulting system of partial differential equations for the multicell spheroid case are compared with closed form solutions of the monolayer case, particularly with respect to the effects on the cell kill of the drug dosage and of the duration of its application." | 1.32 | Mathematical modelling of drug transport in tumour multicell spheroids and monolayer cultures. ( King, JR; Ward, JP, 2003) |
| "Mitomycin C (MMC) is a clinically used anticancer drug that is reduced to cytotoxic metabolites by cellular reductases via a process known as bioreductive drug activation." | 1.31 | Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: implications for enzyme-directed bioreductive drug development. ( Burger, AM; Fiebig, HH; Jarrett, CM; Loadman, PM; Phillips, RM; Swaine, DJ, 2000) |
| "The vital status and cancer development was followed using the National Death Registry, Cancer Registry, and Blackfoot Disease Registry." | 1.31 | The association between frequencies of mitomycin C-induced sister chromatid exchange and cancer risk in arseniasis. ( Chen, CJ; Chen, YH; Hsieh, LL; Liou, SH; Loh, CH; Wu, TN; Yang, T, 2002) |
| "In 10 human cancer cell lines, the activity of mitomycin C (MMC) was found to be determined by an interplay between activation by DT-diaphorase (DTD) and inactivation by glutathione S-transferase (GST)." | 1.30 | Molecular targeting of mitomycin C chemotherapy. ( Kumazaki, T; Kurisu, K; Nishiyama, M; Okamura, T; Suzuki, K; Toge, T; Yamamoto, W, 1997) |
| " thymidine or TdR, and bromodeoxyuridine or BrdU) and expression of proliferating cell nuclear antigen (PCNA), as molecular pharmacodynamic endpoints in evaluation of anticancer drug effect in human solid tumors." | 1.30 | Proliferation indices as molecular pharmacodynamic endpoints in evaluation of anticancer drug effect in human solid tumors. ( Au, JL; Gan, Y; Weaver, JR, 1998) |
| " CGP 69846A, in combination with cisplatin, showed superadditive antitumor effects against PC3 human prostate carcinomas with tumor cures, and in combination with mitomycin C, superadditive antitumor effects of CGP 69846A with tumor cures against NCI-H460 large cell lung carcinoma were found." | 1.30 | Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice. ( Fabbro, D; Geiger, T; Monia, BP; Müller, M, 1997) |
| "High degree of mutagen sensitivity in cancer patients may also be playing a major role in cancer onset at an early age." | 1.30 | Mitomycin C induced chromosomal aberrations in young cancer patients. ( Alladi, P; Bakshi, SR; Bhatavdekar, JM; Patel, DD; Patel, RK; Rawal, UM; Roy, SK; Shah, PM; Trivedi, AH, 1998) |
| "The recurrent tumors are suggested to be sensitive to the agents as follows: locally recurrent solid tumors, 5-FU; distantly recurrent solid tumors, 5-FU and CDDP; locally recurrent effusion, CDDP; distantly recurrent effusion, ADR." | 1.29 | Anticancer chemosensitivity changes between the original and recurrent tumors after successful chemotherapy selected according to the sensitivity assay. ( Araya, S; Hayashi, H; Imamura, M; Ishigami, S; Kawabata, K; Masai, Y; Nio, Y; Tamura, K; Tsubono, M, 1995) |
| "Pharmacokinetic study of anticancer drug is essential for clinical application of cancer chemotherapy." | 1.29 | [Clinical application of drug delivery system of anti-cancer drugs--the pharmacokinetics and clinical results]. ( Hagiwara, A; Takahashi, T; Taniguchi, H; Yamaguchi, T, 1993) |
| "Effects of anticancer antibiotics vary due to the variety of the mechanism of action of the antibiotics." | 1.29 | [Biological basis of thermochemotherapy]. ( Hayashi, S; Kano, E; Kawahara, K; Ohtsubo, T; Yamazaki, Y; Zhang, SW, 1993) |
| "A patient with breast cancer was treated with adoptive immunotherapy of CTL because she had severe side effect from antineoplastics ." | 1.28 | [Basic and clinical study of adoptive immunotherapy using cytotoxic T lymphocyte (CTL) against cancers]. ( Kitsukawa, K, 1989) |
| "Mitomycin C(MMC) was bound to Dextran sulphate." | 1.28 | [Application of immunotoxin in cancer therapy; its usefulness and problems in the future]. ( Kitamura, K; Noguchi, A; Takahashi, T; Yamaguchi, T, 1989) |
| "A care system for cancer bearing patients at a highly advanced stage should be informed by a better quality of life based on a life style of the patients and their families." | 1.28 | [Nutritional support for cancer bearing patients]. ( Yamada, S, 1991) |
| " These findings suggested that arterial infusion chemotherapy in combination with biochemical modulation was a safe and effective method for treating cancer patients." | 1.28 | [Arterial infusion chemotherapy combined with biochemical modulation in cancer patients]. ( Mai, M; Ogino, T; Suga, T; Takahashi, Y, 1991) |
| " At this time the ITC therapy is used in combination with induced-hypertension-chemotherapy (IHC therapy)." | 1.27 | [The clinical effect of hyperthermia combined with induced hypertension chemotherapy]. ( Hayashida, S; Kobayashi, T; Sugimoto, K, 1984) |
| "Additionally, allogeneic tumors totally inhibit lysis of autologous tumor cells in other cold target studies." | 1.27 | The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymp ( Grimm, EA; Wilson, DJ, 1985) |
| "The PR cases were 4 of stomach cancer and 2 of lung cancer, the former being all undifferentiated adenocarcinoma." | 1.27 | [Phase II study of KW 2083 [7-N-(p-hydroxyphenyl)-mitomycin C] in patients with various cancers]. ( Harashima, S; Kanko, T; Nakao, I; Nishi, I; Ohashi, Y; Saito, T; Yokoyama, T, 1984) |
| " The anticancer effects were more enhanced when TBHT was combined with dosage of cis-DDP." | 1.27 | [Total-body hyperthermia and combined anticancer chemotherapy]. ( Koga, S; Maeta, M, 1985) |
| "Of 211 measurable tumors, 74 (35%) showed a marked tumor reduction greater than 50%, 77 (37%) showed a moderate reduction less than 50% and 60 (28%) failed to respond." | 1.27 | [Selective arterial chemo-embolization with microencapsulated anticancer drugs]. ( Kato, T, 1983) |
| "One case of each of ovarian cancer and gastric cancer showed minor response." | 1.27 | [A clinical trial of a new mitomycin C derivative, KW-2083 (7-N-(p-hydroxyphenyl)-mitomycin C)]. ( Takahashi, H; Takahashi, K; Wakui, A; Yokoyama, M, 1985) |
| "Solid tumors are known to contain hypoxic cells and are relatively resistant to ionizing radiation and some chemotherapeutic agents." | 1.27 | Cytotoxicity of mitomycin C on clonogenic human carcinoma cells is not enhanced by hypoxia. ( Beaudry, JN; Ludwig, CU; Peng, YM; Salmon, SE, 1984) |
| "Metronidazole, 1." | 1.27 | Feasibility study of combining metronidazole with chemotherapy. ( Bélanger, R; Crook, AF; Heringer, R; Hopkins, HS; Hugenholtz, H; Maroun, JA; Richard, MT; Stewart, DJ; Yan, RC; Young, V, 1983) |
| "This paper describes an investigation into the pharmacokinetic behavior of mitomycin C (MMC) in 36 patients receiving either single-agent chemotherapy (10 to 20 mg/sq m), or a combination regimen including MMC (5 to 10 mg/sq m)." | 1.27 | Pharmacokinetics of mitomycin C in humans. ( den Hartigh, J; McVie, JG; Pinedo, HM; van Oort, WJ, 1983) |
| "This finding could be applied to cancer chemotherapy for enhancing drug delivery to tumor tissue selectively." | 1.27 | [Cancer chemotherapy in combination with angiotensin-induced hypertension]. ( Suzuki, M; Wakui, A, 1983) |
| "Namely, most solid tumors possess four different unique features: hypervasculature, enhanced permeability even to macromolecules, architectural differences, and lack of the lymphatic recovery system." | 1.27 | [Tumor-targeted chemotherapy with lipid contrast medium and macro molecular anticancer agents theoretical considerations and clinical outcome]. ( Konno, T; Maeda, H, 1985) |
| " From these results, it was suggested that the release speed of anti-cancer agents can be controlled by modifying the drug dosage and form." | 1.27 | [Basic study of anti-cancer agents suspended in lipiodol]. ( Takahashi, T; Taniguchi, H; Yamaguchi, T, 1986) |
| "It is desirable for multidisciplinary cancer treatments to be concentrated as selectively as possible onto the cancer-bearing organs in order to augment the anticancer effects and minimize the untoward effects." | 1.27 | [Combination of selective intra-arterial infusion of an anticancer agent via the vascular access port with RF local hyperthermia]. ( Agishi, T; Fuchinoue, S; Honda, H; Nakazawa, H; Okumura, T; Teraoka, S, 1986) |
| "Tumors in this study were 16 gastric cancers, five breast cancers, four liposarcomas, three colon cancers, two gall bladder cancers, two esophageal cancers, and one hepatoma." | 1.27 | [In vitro phase II-III study by clonogenic assay: the combined effects of mitomycin C with alpha-interferon]. ( Hattori, T; Hirabayashi, N; Niimoto, M; Nishiyama, M; Nosoh, Y; Toge, T; Yamaguchi, M; Yoshinaka, K, 1986) |
| "The growth of Meth A (MA) tumors was suppressed in tumor-antigen-specific manner in BALB/c mice immunized with mitomycin C-treated MA (MMC-MA) cells in saline or in Freund's complete adjuvant (FCA)." | 1.27 | Differing contribution of various effector cells in the elimination of syngeneic or allogeneic cells. ( Himeno, K; Matsumoto, T; Miake, S; Mitani, M; Mori, K; Nomoto, K, 1986) |
| " Pharmacokinetic studies using HPLC technique were done in nine patients." | 1.27 | High-dose mitomycin-C with autologous bone marrow transplantation in patients with refractory malignancies. Influence of dose schedule on pharmacokinetics and nonhematopoietic toxicities. ( Baker, LH; Emmer, D; Hoschner, JA; Karanes, C; Leichman, L; Ratanatharathorn, V; Schilcher, RB; Young, JD, 1986) |
| "Furosemide was administered prior to, or 120 min after MMC." | 1.27 | Absence of interaction between furosemide and mitomycin C. ( de Vries, J; Kerpel-Fronius, S; Pinedo, HM; Stuurman, M; Verweij, J, 1987) |
| "Selective delivery of anticancer agent, SMANCS was also proved by measurement of its biological activities of removed specimen." | 1.27 | [Arterial administration of SMANCS and other antitumor agents dissolved in lipiodol for various malignant solid tumors]. ( Iwai, K; Konno, T; Maeda, H; Maki, S; Miyauchi, Y; Tashiro, S; Yokoyama, I, 1984) |
| "Tissues used included 27 gastric cancers, 10 breast cancers, 7 colorectal cancers, 4 gallbladder cancers, 4 sarcomas, 3 lymphomas, and 5 other tumors." | 1.27 | Comparative studies on in vitro human tumor clonogenic assay (HTCA) and in vivo nude mouse-isotope assay (NM-IA). ( Hattori, T; Hirabayashi, N; Niimi, K; Niimoto, M; Nishiyama, M; Noso, Y; Toge, T; Yamaguchi, M, 1987) |
| "Hypoxic cells of solid tumors are relatively resistant to therapeutic assault." | 1.27 | Therapeutic attack of hypoxic cells of solid tumors: presidential address. ( Sartorelli, AC, 1988) |
| "Mitomycin C (MMC) has been known to be nephrotoxic since 1971." | 1.27 | Mitomycin C-induced renal toxicity, a dose-dependent side effect? ( de Vries, J; Pinedo, HM; Verwey, J, 1987) |
| "The pharmacokinetic plasma profile of mitomycin C (MMC) was studied during sequential courses in man." | 1.27 | The pharmacokinetic plasma profile of mitomycin C, measured after sequential intermittent intravenous administration. ( Lankelma, J; Pinedo, HM; Stuurman, M; van Bochove, A; van Hoogenhuijze, J; Vermorken, JB; Verweij, J, 1988) |
| " Data on dose dependency or incidence concerning this side effect were not known." | 1.27 | A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C. ( Funke-Küpper, AJ; Pinedo, HM; Teule, GJ; Verweij, J, 1988) |
| " Eleven additional patients were evaluated for tolerance to repeated 6-ml dosing of DSM." | 1.27 | Phase I study of hepatic arterial degradable starch microspheres and mitomycin. ( Ensminger, WD; Gyves, JW; Stetson, P; Walker-Andrews, S, 1985) |
| "Cellular subpopulations of solid tumors can be divided into compartments based upon their degree of oxygenation and their rate of proliferation." | 1.26 | Hypoxic cell specific chemotherapeutic agents. ( Sartorelli, AC, 1982) |
| "The levels of anticancer drugs in tissue were measured by bioassay method in 28 patients with gastrointestinal cancer, who were treated with intravenous administration of 500 mg of 5-FU combined with ANG-II during surgery." | 1.26 | [Clinical studies of cancer chemotherapy combined with angiotensin-II (ANG-II)]. ( Kanno, H; Kikuchi, K; Kunii, Y; Takahashi, N, 1982) |
| "Seventy tumors (56." | 1.26 | [Chemosensitivity of adriamycin, mitomycin C, and bleomycin with in vitro colony assay]. ( Arakawa, M; Inoue, K; Miyamoto, H; Ogawa, M, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 156 (54.36) | 18.7374 |
| 1990's | 47 (16.38) | 18.2507 |
| 2000's | 43 (14.98) | 29.6817 |
| 2010's | 30 (10.45) | 24.3611 |
| 2020's | 11 (3.83) | 2.80 |
| Authors | Studies |
|---|---|
| Kakadiya, R | 1 |
| Dong, H | 1 |
| Lee, PC | 1 |
| Kapuriya, N | 1 |
| Zhang, X | 2 |
| Chou, TC | 1 |
| Lee, TC | 1 |
| Kapuriya, K | 1 |
| Shah, A | 1 |
| Su, TL | 1 |
| Sondhi, SM | 1 |
| Rani, R | 1 |
| Singh, J | 1 |
| Roy, P | 1 |
| Agrawal, SK | 1 |
| Saxena, AK | 2 |
| Rajak, H | 1 |
| Agarawal, A | 1 |
| Parmar, P | 1 |
| Thakur, BS | 1 |
| Veerasamy, R | 1 |
| Sharma, PC | 1 |
| Kharya, MD | 1 |
| Kraicheva, I | 1 |
| Tsacheva, I | 1 |
| Vodenicharova, E | 1 |
| Tashev, E | 1 |
| Tosheva, T | 1 |
| Kril, A | 1 |
| Topashka-Ancheva, M | 1 |
| Iliev, I | 1 |
| Gerasimova, Ts | 1 |
| Troev, K | 1 |
| Majeed, R | 1 |
| Reddy, MV | 1 |
| Chinthakindi, PK | 1 |
| Sangwan, PL | 1 |
| Hamid, A | 1 |
| Chashoo, G | 1 |
| Koul, S | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 2 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 2 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Cheng, G | 1 |
| Hardy, M | 1 |
| You, M | 1 |
| Kalyanaraman, B | 1 |
| Sapir, E | 2 |
| Pfeffer, R | 1 |
| Wygoda, M | 1 |
| Purim, O | 1 |
| Levy, A | 1 |
| Corn, B | 1 |
| Amitay, Y | 4 |
| Ohana, P | 4 |
| Gabizon, A | 3 |
| Tariq, MR | 1 |
| Ali, SW | 1 |
| Fatima, N | 1 |
| Jabeen, A | 1 |
| Qazi, AS | 1 |
| Hameed, A | 1 |
| Safdar, W | 1 |
| Gul, SK | 1 |
| Tepetam, H | 1 |
| Yildiz, F | 1 |
| Er, I | 1 |
| Oksuz, DC | 1 |
| Parvizi, M | 1 |
| Ozden, AS | 1 |
| Alicikus, ZA | 1 |
| Sari, SY | 1 |
| Alomari, O | 1 |
| Gorken, IB | 1 |
| Seavers, A | 1 |
| Robson, D | 1 |
| Weingarth, JM | 1 |
| Shmeeda, H | 3 |
| Tahover, E | 2 |
| Kornev, G | 1 |
| Patil, Y | 2 |
| Zalipsky, S | 1 |
| Seita, A | 1 |
| Nakaoka, H | 1 |
| Okura, R | 1 |
| Wakamoto, Y | 1 |
| Calvo, JA | 1 |
| Fritchman, B | 1 |
| Hernandez, D | 1 |
| Persky, NS | 1 |
| Johannessen, CM | 1 |
| Piccioni, F | 1 |
| Kelch, BA | 1 |
| Cantor, SB | 1 |
| De Jesus Perez, VA | 1 |
| Zamanian, RT | 1 |
| Meyer, FB | 1 |
| Goebel, S | 1 |
| Spangel, SB | 1 |
| Leovsky, C | 1 |
| Hoelzer, D | 1 |
| Thierbach, R | 1 |
| Hu, F | 1 |
| Yuan, Y | 1 |
| Mao, D | 1 |
| Wu, W | 1 |
| Liu, B | 1 |
| Zhang, RX | 1 |
| Zhang, T | 1 |
| Chen, K | 1 |
| Cheng, J | 1 |
| Lai, P | 1 |
| Rauth, AM | 5 |
| Pang, KS | 1 |
| Wu, XY | 1 |
| Tay, LS | 1 |
| Krishnan, V | 1 |
| Sankar, H | 1 |
| Chong, YL | 1 |
| Chuang, LSH | 1 |
| Tan, TZ | 1 |
| Kolinjivadi, AM | 1 |
| Kappei, D | 1 |
| Ito, Y | 1 |
| Jordheim, LP | 1 |
| Barakat, KH | 1 |
| Heinrich-Balard, L | 1 |
| Matera, EL | 1 |
| Cros-Perrial, E | 1 |
| Bouledrak, K | 1 |
| El Sabeh, R | 1 |
| Perez-Pineiro, R | 1 |
| Wishart, DS | 1 |
| Cohen, R | 1 |
| Tuszynski, J | 1 |
| Dumontet, C | 1 |
| Torres, NP | 1 |
| Lee, AY | 1 |
| Giaever, G | 1 |
| Nislow, C | 1 |
| Brown, GW | 1 |
| Martínez, S | 1 |
| Pérez, L | 1 |
| Galmarini, CM | 1 |
| Aracil, M | 1 |
| Tercero, JC | 1 |
| Gago, F | 1 |
| Albella, B | 1 |
| Bueren, JA | 1 |
| Aggarwal, M | 1 |
| Banerjee, T | 2 |
| Sommers, JA | 2 |
| Brosh, RM | 2 |
| Bharti, SK | 1 |
| Khan, I | 1 |
| Wu, Y | 3 |
| Bhanot, A | 1 |
| Sharma, R | 1 |
| Singh, S | 2 |
| Noolvi, MN | 1 |
| El Hosry, L | 1 |
| Di Giorgio, C | 1 |
| Birer, C | 1 |
| Habib, J | 1 |
| Tueni, M | 1 |
| Bun, SS | 1 |
| Herbette, G | 1 |
| De Meo, M | 1 |
| Ollivier, E | 1 |
| Elias, R | 1 |
| Suzuki, T | 1 |
| Golan, T | 1 |
| Grenader, T | 1 |
| La-Beck, NM | 1 |
| Berger, R | 2 |
| Gabizon, AA | 1 |
| Villalona-Calero, MA | 3 |
| Duan, W | 2 |
| Zhao, W | 1 |
| Shilo, K | 1 |
| Schaaf, LJ | 2 |
| Thurmond, J | 1 |
| Westman, JA | 1 |
| Marshall, J | 1 |
| Xiaobai, L | 1 |
| Ji, J | 1 |
| Rose, J | 1 |
| Lustberg, M | 1 |
| Bekaii-Saab, T | 1 |
| Chen, A | 1 |
| Timmers, C | 1 |
| Garcia, G | 1 |
| Atallah, JP | 1 |
| Xu, Y | 1 |
| Kolesar, JM | 2 |
| Drengler, R | 1 |
| Otterson, G | 1 |
| Shapiro, C | 1 |
| Kuhn, J | 1 |
| Cowen, RL | 2 |
| Garside, EJ | 1 |
| Fitzpatrick, B | 1 |
| Papadopoulou, MV | 1 |
| Williams, KJ | 2 |
| Ota, K | 4 |
| Kurita, S | 1 |
| Nishimura, M | 2 |
| Ogawa, M | 2 |
| Kamei, Y | 1 |
| Imai, K | 1 |
| Ariyoshi, Y | 1 |
| Kataoka, K | 1 |
| Murakami, M | 1 |
| Oyama, A | 1 |
| Hoshino, A | 1 |
| Amo, H | 1 |
| Kato, T | 4 |
| Kulcsár, G | 1 |
| Marietta, C | 1 |
| Thompson, LH | 1 |
| Lamerdin, JE | 1 |
| Brooks, PJ | 1 |
| Auerbach, AD | 1 |
| Martins, I | 1 |
| Tesniere, A | 2 |
| Kepp, O | 1 |
| Michaud, M | 1 |
| Schlemmer, F | 1 |
| Senovilla, L | 1 |
| Séror, C | 1 |
| Métivier, D | 2 |
| Perfettini, JL | 1 |
| Zitvogel, L | 2 |
| Kroemer, G | 2 |
| Glockzin, G | 1 |
| Renner, P | 1 |
| Popp, FC | 1 |
| Dahlke, MH | 1 |
| von Breitenbuch, P | 1 |
| Schlitt, HJ | 1 |
| Piso, P | 1 |
| Li, M | 1 |
| Qiu, Y | 1 |
| Yao, Z | 1 |
| Liu, S | 1 |
| Liu, Y | 1 |
| Shi, J | 1 |
| Zheng, D | 1 |
| Siegel, D | 1 |
| Yan, C | 1 |
| Ross, D | 1 |
| Cartei, G | 1 |
| Colombrino, E | 1 |
| Sanzari, MC | 1 |
| Plebani, M | 1 |
| Micucci, M | 1 |
| Fiorica, F | 1 |
| Giraldi, T | 1 |
| Zustovich, F | 1 |
| Cartei, F | 1 |
| Sturm, JB | 1 |
| Hess, M | 1 |
| Weibel, S | 1 |
| Chen, NG | 1 |
| Yu, YA | 1 |
| Zhang, Q | 1 |
| Donat, U | 1 |
| Reiss, C | 1 |
| Gambaryan, S | 1 |
| Krohne, G | 1 |
| Stritzker, J | 1 |
| Szalay, AA | 1 |
| Kislukhin, G | 1 |
| Murphy, ML | 1 |
| Jafari, M | 1 |
| Long, AD | 1 |
| Aapro, M | 1 |
| Dietrich, PY | 1 |
| Leyvraz, S | 1 |
| Cui, S | 1 |
| Ba, M | 1 |
| Tang, Y | 1 |
| Liu, J | 1 |
| Wang, B | 1 |
| Tang, H | 1 |
| Zhong, S | 1 |
| Cheng, H | 1 |
| Hong, B | 1 |
| Allen, JE | 1 |
| Tai, G | 1 |
| Humphreys, R | 1 |
| Dicker, DT | 1 |
| Liu, YY | 1 |
| El-Deiry, WS | 1 |
| Al-Kasspooles, MF | 1 |
| Williamson, SK | 1 |
| Henry, D | 1 |
| Howell, J | 1 |
| Niu, F | 1 |
| Decedue, CJ | 1 |
| Roby, KF | 1 |
| Tsukagoshi, S | 1 |
| Takahashi, T | 5 |
| Ward, JP | 1 |
| King, JR | 1 |
| Inoue, N | 1 |
| Yamasaki, S | 1 |
| Kondo, K | 2 |
| Kan, T | 1 |
| Furumoto, K | 1 |
| Imamura, M | 2 |
| USUBUCHI, I | 2 |
| OBOSHI, S | 2 |
| TSUCHIDA, R | 1 |
| TANABE, H | 1 |
| SUGIURA, K | 2 |
| Shimizu, M | 1 |
| Matsuzawa, A | 1 |
| Takeda, Y | 1 |
| OHTA, F | 1 |
| MIYANAMI, M | 1 |
| SCHMIDT, CG | 1 |
| MIRO-QUESADA, O | 1 |
| AYULO, VM | 1 |
| ADACHI, L | 1 |
| CABRAI, F | 1 |
| HATTORI, T | 7 |
| OKADA, K | 1 |
| SEKIGUCHI, M | 1 |
| ASHIKAWA, K | 1 |
| MOTOYA, K | 1 |
| ENDO, S | 3 |
| ISHIBASHI, Y | 2 |
| MERKER, PC | 2 |
| REYES, C | 1 |
| ANIDO, P | 1 |
| ISHIDA, T | 1 |
| TAKAHASHI, N | 2 |
| KIMURA, S | 1 |
| REEVE, TS | 1 |
| TAZAKI, Y | 1 |
| HOSSENLOPP, C | 1 |
| SATO, M | 1 |
| DAWSON, EM | 1 |
| KUBOTA, J | 1 |
| IWATA, S | 1 |
| KAGEYAMA, T | 2 |
| HANO, S | 1 |
| ISHII, H | 1 |
| WAKABAYASHI, A | 1 |
| WADA, M | 1 |
| KURISU, T | 1 |
| FUJII, M | 1 |
| TSUTSUMI, T | 1 |
| FUKUSHIMA, K | 1 |
| KANEKO, K | 1 |
| AKASHI, T | 1 |
| SHINDO, H | 1 |
| SASSA, T | 1 |
| OTSUKA, Y | 1 |
| SAKURAI, Y | 2 |
| MORIWAKI, A | 1 |
| LANGDON, EA | 2 |
| OTTOMAN, RE | 2 |
| ROCHLIN, DB | 3 |
| SMART, CR | 3 |
| GOLDENBERG, DM | 1 |
| HIGUCHI, K | 1 |
| UEMATSU, K | 1 |
| ISHIHARA, M | 1 |
| TERAO, S | 1 |
| HASHIGO, H | 1 |
| THIELE, EH | 1 |
| ARISON, RN | 1 |
| BOXER, GE | 1 |
| KOOP, CE | 2 |
| MARSHALL, SF | 1 |
| TANIDA, T | 1 |
| BROCKMAN, RW | 2 |
| ANDERSON, EP | 1 |
| FUJIMORI, M | 1 |
| SAKAUCHI, G | 1 |
| IZUO, M | 2 |
| ABE, C | 1 |
| MORITA, S | 1 |
| NASHIMOTO, T | 1 |
| ISHIKAWA, S | 1 |
| SADMITSU, H | 1 |
| KAWAI, T | 1 |
| IMANAGA, H | 1 |
| SHIRAHA, Y | 1 |
| OMURA, Y | 1 |
| SUZUKI, M | 2 |
| SUZUKI, K | 2 |
| OHASHI, D | 1 |
| SAITO, K | 1 |
| HAYASE, T | 1 |
| KOMATSU, K | 1 |
| MORI, K | 3 |
| KAWAMURA, Y | 1 |
| KIDO, C | 1 |
| OKADA, S | 1 |
| KATO, K | 1 |
| ITO, I | 1 |
| KOYAMA, Y | 1 |
| FUJITA, H | 2 |
| ITO, H | 1 |
| MIWA, K | 1 |
| HIRATA, K | 1 |
| KANAGAMI, H | 1 |
| NIITANI, K | 1 |
| KATSURA, T | 1 |
| KNOCK, FE | 1 |
| HANDLER, AH | 1 |
| SARRIS, TG | 1 |
| WILLS, C | 1 |
| KONDO, T | 2 |
| SOKOLOFF, B | 1 |
| MCCONNELL, B | 1 |
| HIBINO, S | 1 |
| MILLER, E | 1 |
| SULLIVAN, RD | 1 |
| AUSMAN, RK | 2 |
| AUST, JB | 1 |
| SUGIMURA, K | 1 |
| UENO, K | 1 |
| MYHRE, K | 1 |
| FJAERLI, J | 1 |
| GERBER, P | 1 |
| CENTARO, A | 1 |
| GASPARRI, F | 1 |
| MAIJNELLI, M | 1 |
| PERITI, P | 1 |
| KOIZUMI, A | 2 |
| YOSHIDA, K | 1 |
| YAMAGUCHI, I | 1 |
| MAJIMA, S | 1 |
| FUJIWARA, Y | 1 |
| AOYAMA, T | 1 |
| WAKISAKA, G | 1 |
| UCHINO, H | 1 |
| NAKAMURA, T | 2 |
| SHIRAKAWA, S | 1 |
| ADACHI, A | 1 |
| SAKURAI, M | 1 |
| MIYAMOTO, K | 1 |
| YAMADA, K | 1 |
| TEWARSON, IP | 1 |
| KADONO, T | 1 |
| STRAUB, PW | 1 |
| NELSON, JH | 1 |
| MARIK, LR | 1 |
| BURCHENAL, JH | 1 |
| SAKAI, S | 1 |
| SAITO, G | 1 |
| SUGAYAMA, J | 1 |
| KAMASUKA, T | 1 |
| TAKANO, T | 1 |
| TAKADA, S | 1 |
| HAGIHARA, K | 1 |
| CLAPP, P | 1 |
| TAYAO, MS | 1 |
| TYREE, EB | 1 |
| NICKSON, JJ | 1 |
| CLARKSON, B | 1 |
| LAWRENCE, W | 1 |
| EVANS, JS | 1 |
| BOSTWICK, L | 1 |
| MENGEL, GD | 1 |
| BRADNER, WT | 2 |
| BACHMAN, S | 1 |
| PINDELL, MH | 1 |
| WRIGHT, JC | 1 |
| LYONS, MM | 1 |
| WALKER, DG | 1 |
| GOLOMB, FM | 1 |
| GUMPORT, SL | 1 |
| MEDREK, TJ | 1 |
| WATANABE, T | 1 |
| IZUCHI, S | 1 |
| NGU, VA | 1 |
| HIRONO, I | 1 |
| KOJIMA, K | 1 |
| KACHI, H | 1 |
| OHASHI, A | 2 |
| SASAOKA, I | 1 |
| KOSHIURA, R | 1 |
| KOSHIMURA, S | 1 |
| BANDO, Y | 1 |
| NIITANI, H | 1 |
| SUZUKI, A | 1 |
| SHIMOYAMA, M | 1 |
| KIMURA, K | 1 |
| KIKUCHI, K | 2 |
| ANEHA, Y | 1 |
| YAMANAKA, M | 1 |
| TANEICHI, T | 1 |
| NATSUME, R | 1 |
| KANNO, H | 2 |
| NAGANUMA, H | 1 |
| SATO, Y | 1 |
| YOSHIZUMI, M | 1 |
| KUNII, Y | 2 |
| SATO, T | 1 |
| YAMAGATA, S | 1 |
| WATANABE, R | 1 |
| DAWSON, PJ | 1 |
| FIELDSTEEL, AH | 1 |
| BOSTICK, WL | 1 |
| INOKUCHI, K | 1 |
| IENAGA, S | 1 |
| AKIYOSHI, T | 5 |
| IKEDA, T | 1 |
| RAPP, F | 1 |
| BUTEL, JS | 1 |
| FELDMAN, LA | 1 |
| KITAHARA, T | 1 |
| MELNICK, JL | 1 |
| TANAKA, N | 1 |
| SILVA, AR | 1 |
| HUMPHREY, EW | 1 |
| HYMES, AC | 1 |
| FERGUSON, DJ | 1 |
| KERSTEN, H | 1 |
| MATSUYAMA, M | 1 |
| Celli, CM | 1 |
| Jaiswal, AK | 1 |
| Suggitt, M | 1 |
| Fearnley, J | 1 |
| Swaine, DJ | 2 |
| Volpato, M | 1 |
| Phillips, RM | 2 |
| Bibby, MC | 1 |
| Loadman, PM | 2 |
| Anderson, D | 1 |
| Potter, C | 1 |
| Harris, AL | 2 |
| Fang, J | 1 |
| Sawa, T | 1 |
| Akaike, T | 1 |
| Greish, K | 1 |
| Maeda, H | 3 |
| Tanaka, T | 1 |
| Shiramoto, S | 1 |
| Miyashita, M | 1 |
| Fujishima, Y | 1 |
| Kaneo, Y | 1 |
| McPherson, JP | 1 |
| Lemmers, B | 1 |
| Chahwan, R | 1 |
| Pamidi, A | 1 |
| Migon, E | 1 |
| Matysiak-Zablocki, E | 1 |
| Moynahan, ME | 1 |
| Essers, J | 1 |
| Hanada, K | 1 |
| Poonepalli, A | 1 |
| Sanchez-Sweatman, O | 1 |
| Khokha, R | 1 |
| Kanaar, R | 1 |
| Jasin, M | 1 |
| Hande, MP | 1 |
| Hakem, R | 1 |
| Danson, S | 1 |
| Ward, TH | 1 |
| Butler, J | 1 |
| Ranson, M | 1 |
| Chow, TY | 1 |
| Alaoui-Jamali, MA | 1 |
| Yeh, C | 1 |
| Yuen, L | 1 |
| Griller, D | 1 |
| Wu, K | 1 |
| Hinson, SR | 1 |
| Farrugia, D | 1 |
| Wendt, P | 1 |
| Tavtigian, SV | 1 |
| Deffenbaugh, A | 1 |
| Goldgar, D | 1 |
| Couch, FJ | 1 |
| Digby, T | 1 |
| Leith, MK | 1 |
| Thliveris, JA | 1 |
| Begleiter, A | 2 |
| Misirli, Y | 1 |
| Oztürk, E | 1 |
| Kurşaklioğlu, H | 1 |
| Denkbaş, EB | 1 |
| Watne, AL | 1 |
| Moore, D | 1 |
| Gorgun, B | 1 |
| Casares, N | 1 |
| Pequignot, MO | 1 |
| Ghiringhelli, F | 1 |
| Roux, S | 1 |
| Chaput, N | 1 |
| Schmitt, E | 1 |
| Hamai, A | 1 |
| Hervas-Stubbs, S | 1 |
| Obeid, M | 1 |
| Coutant, F | 1 |
| Pichard, E | 1 |
| Aucouturier, P | 1 |
| Pierron, G | 1 |
| Garrido, C | 1 |
| Barak, Y | 1 |
| Thorne, SH | 1 |
| Ackerley, DF | 1 |
| Lynch, SV | 1 |
| Contag, CH | 1 |
| Matin, A | 1 |
| Garofalo, A | 1 |
| Valle, M | 1 |
| Garcia, J | 1 |
| Sugarbaker, PH | 1 |
| Heng, HH | 1 |
| Stevens, JB | 1 |
| Liu, G | 1 |
| Bremer, SW | 1 |
| Ye, KJ | 1 |
| Reddy, PV | 1 |
| Wu, GS | 1 |
| Wang, YA | 1 |
| Tainsky, MA | 1 |
| Ye, CJ | 1 |
| Rahman-Roblick, R | 1 |
| Roblick, UJ | 1 |
| Hellman, U | 1 |
| Conrotto, P | 1 |
| Liu, T | 1 |
| Becker, S | 1 |
| Hirschberg, D | 1 |
| Jörnvall, H | 1 |
| Auer, G | 1 |
| Wiman, KG | 1 |
| McKeown, SR | 1 |
| Ernst, T | 1 |
| Merx, K | 1 |
| Gnad-Vogt, U | 1 |
| Lukan, N | 1 |
| Kripp, M | 1 |
| Schultheis, B | 1 |
| Hochhaus, A | 1 |
| Hofheinz, RD | 1 |
| Guay, D | 1 |
| Garand, C | 1 |
| Reddy, S | 1 |
| Schmutte, C | 1 |
| Lebel, M | 1 |
| Müller, LU | 1 |
| Milsom, MD | 1 |
| Kim, MO | 1 |
| Schambach, A | 1 |
| Schuesler, T | 1 |
| Williams, DA | 1 |
| Glen, CD | 1 |
| Smith, AG | 1 |
| Dubrova, YE | 1 |
| Sezaki, H | 2 |
| Hashida, M | 2 |
| Konno, T | 2 |
| Iwai, K | 1 |
| Maki, S | 1 |
| Tashiro, S | 1 |
| Miyauchi, Y | 1 |
| Yokoyama, I | 1 |
| Miyamoto, H | 1 |
| Inoue, K | 1 |
| Arakawa, M | 1 |
| Imamishi, J | 1 |
| Tanaka, A | 1 |
| Tanigawa, N | 1 |
| Mizuno, Y | 1 |
| Hashimura, T | 1 |
| Honda, K | 2 |
| Satomura, K | 2 |
| Hikasa, Y | 1 |
| Niwa, O | 1 |
| Sugahara, T | 1 |
| Yoshida, O | 1 |
| Kern, DH | 1 |
| Hayashida, S | 1 |
| Sugimoto, K | 1 |
| Kobayashi, T | 2 |
| Bottazzi, B | 1 |
| Polentarutti, N | 1 |
| Balsari, A | 1 |
| Boraschi, D | 1 |
| Ghezzi, P | 1 |
| Salmona, M | 1 |
| Mantovani, A | 1 |
| Lokich, JJ | 1 |
| Perri, J | 1 |
| Bothe, A | 1 |
| Zipoli, T | 1 |
| Philips, D | 1 |
| Sonneborn, H | 1 |
| Paul, S | 1 |
| Green, R | 1 |
| Wakui, A | 3 |
| Saijo, N | 1 |
| Koga, S | 2 |
| Izumi, A | 1 |
| Maeta, M | 2 |
| Shimizu, N | 1 |
| Osaki, Y | 1 |
| Kanayama, H | 1 |
| den Hartigh, J | 1 |
| McVie, JG | 1 |
| van Oort, WJ | 1 |
| Pinedo, HM | 7 |
| van Hazel, GA | 1 |
| Scott, M | 1 |
| Rubin, J | 1 |
| Moertel, CG | 1 |
| Eagan, RT | 1 |
| O'Connell, MJ | 1 |
| Kovach, JS | 1 |
| Andrysek, O | 1 |
| Stewart, DJ | 1 |
| Maroun, JA | 1 |
| Young, V | 1 |
| Crook, AF | 1 |
| Hopkins, HS | 1 |
| Yan, RC | 1 |
| Richard, MT | 1 |
| Hugenholtz, H | 1 |
| Bélanger, R | 1 |
| Heringer, R | 1 |
| Ludwig, CU | 1 |
| Peng, YM | 1 |
| Beaudry, JN | 1 |
| Salmon, SE | 1 |
| Bull, JM | 1 |
| Sato, H | 2 |
| Ludwig, C | 1 |
| Smolianskaia, AZ | 1 |
| Spasibina, TV | 1 |
| Le, J | 1 |
| Yip, YK | 1 |
| Vilcek, J | 1 |
| Meguro, S | 1 |
| Nagata, T | 1 |
| Yokoyama, K | 1 |
| Chinen, T | 1 |
| Yamazaki, H | 1 |
| Kuraishi, Y | 1 |
| Abe, M | 2 |
| Isogai, Y | 1 |
| Nishi, I | 1 |
| Yokoyama, T | 1 |
| Nakao, I | 1 |
| Harashima, S | 1 |
| Ohashi, Y | 1 |
| Kanko, T | 1 |
| Saito, T | 2 |
| Body, JJ | 1 |
| Rozencweig, M | 1 |
| Kenis, Y | 1 |
| Nemoto, R | 1 |
| Carter, WH | 1 |
| Wampler, GL | 1 |
| Stablein, DM | 1 |
| Campbell, ED | 1 |
| Sartorelli, AC | 3 |
| Yamamoto, M | 1 |
| Pritsos, CA | 2 |
| Gustafson, DL | 1 |
| Hodnick, WF | 1 |
| Belcourt, MF | 1 |
| Tomasz, M | 2 |
| Haffty, B | 1 |
| Fischer, JJ | 1 |
| Rockwell, S | 1 |
| Margolin, KA | 1 |
| Akman, SA | 1 |
| Leong, LA | 1 |
| Morgan, RJ | 1 |
| Somlo, G | 1 |
| Raschko, JW | 1 |
| Ahn, C | 1 |
| Doroshow, JH | 1 |
| Dirix, L | 1 |
| Catimel, G | 1 |
| Koier, I | 1 |
| Provè, A | 1 |
| Schrijvers, D | 1 |
| Joossens, E | 1 |
| De Bruijn, E | 1 |
| Ardiet, C | 1 |
| Evene, E | 1 |
| Dumortier, A | 1 |
| Nio, Y | 2 |
| Tamura, K | 1 |
| Tsubono, M | 1 |
| Kawabata, K | 1 |
| Masai, Y | 1 |
| Hayashi, H | 1 |
| Ishigami, S | 1 |
| Araya, S | 1 |
| Arinaga, S | 4 |
| Karimine, N | 2 |
| Takamuku, K | 2 |
| Nanbara, S | 3 |
| Inoue, H | 2 |
| Abe, R | 2 |
| Watanabe, D | 2 |
| Asoh, T | 1 |
| Ueo, H | 2 |
| Philip, PA | 2 |
| Thompson, CH | 1 |
| Carmichael, J | 1 |
| Rea, D | 1 |
| Mitchell, K | 1 |
| Taylor, DJ | 1 |
| Stuart, NS | 1 |
| Dennis, I | 1 |
| Rajagopalan, B | 1 |
| Ganesan, T | 1 |
| Marshall, RS | 4 |
| Kuehl, BL | 1 |
| Yamaguchi, T | 3 |
| Hagiwara, A | 1 |
| Taniguchi, H | 2 |
| Kano, E | 2 |
| Yamazaki, Y | 1 |
| Hayashi, S | 1 |
| Zhang, SW | 1 |
| Kawahara, K | 1 |
| Ohtsubo, T | 1 |
| Logan, TF | 1 |
| Gooding, W | 1 |
| Kirkwood, JM | 1 |
| Shadduck, RK | 1 |
| Sato, K | 1 |
| Sasaki, R | 1 |
| Kakinuma, H | 1 |
| Moriyama, M | 1 |
| Fitzsimmons, SA | 1 |
| Workman, P | 2 |
| Grever, M | 1 |
| Paull, K | 1 |
| Camalier, R | 1 |
| Lewis, AD | 1 |
| Depenbrock, H | 1 |
| Wenger, M | 1 |
| Peter, R | 1 |
| Fellbaum, C | 1 |
| Block, T | 1 |
| Rastetter, J | 1 |
| Hanauske, AR | 1 |
| Verweij, J | 7 |
| Takakura, Y | 1 |
| Liou, SH | 2 |
| Chen, CJ | 2 |
| van Moorsel, CJ | 1 |
| Veerman, G | 1 |
| Bergman, AM | 1 |
| Guechev, A | 1 |
| Vermorken, JB | 2 |
| Postmus, PE | 1 |
| Peters, GJ | 1 |
| Nishiyama, M | 3 |
| Kumazaki, T | 1 |
| Yamamoto, W | 1 |
| Toge, T | 3 |
| Okamura, T | 1 |
| Kurisu, K | 1 |
| Macaulay, VM | 1 |
| O'Byrne, KJ | 1 |
| Green, JA | 1 |
| McKinley, L | 1 |
| LaCreta, FP | 1 |
| Winograd, B | 2 |
| Ganesan, TS | 1 |
| Talbot, DC | 1 |
| Cummings, J | 1 |
| Spanswick, VJ | 1 |
| Smyth, JF | 1 |
| Weaver, JR | 1 |
| Gan, Y | 1 |
| Au, JL | 2 |
| Geiger, T | 1 |
| Müller, M | 1 |
| Monia, BP | 1 |
| Fabbro, D | 1 |
| Bakshi, SR | 1 |
| Patel, RK | 1 |
| Roy, SK | 1 |
| Alladi, P | 1 |
| Trivedi, AH | 1 |
| Bhatavdekar, JM | 1 |
| Patel, DD | 1 |
| Shah, PM | 1 |
| Rawal, UM | 1 |
| Furue, H | 1 |
| Planting, AS | 1 |
| Schellens, JH | 1 |
| van der Burg, ME | 1 |
| de Boer-Dennert, M | 1 |
| Stoter, G | 1 |
| Shudo, K | 1 |
| Burger, AM | 1 |
| Jarrett, CM | 1 |
| Fiebig, HH | 1 |
| Martin, DS | 1 |
| Bertino, JR | 1 |
| Koutcher, JA | 1 |
| Kozuch, P | 1 |
| Hoff, PM | 1 |
| Hess, K | 1 |
| Adams, J | 1 |
| Newman, RA | 1 |
| Lee, F | 1 |
| Pazdur, R | 1 |
| Stepczynska, A | 1 |
| Lauber, K | 1 |
| Engels, IH | 1 |
| Janssen, O | 1 |
| Kabelitz, D | 1 |
| Wesselborg, S | 1 |
| Schulze-Osthoff, K | 1 |
| Tichler, T | 1 |
| Ghodsizade, E | 1 |
| Katz, A | 1 |
| Rath, P | 1 |
| Brenner, H | 1 |
| Jang, SH | 1 |
| Wientjes, MG | 1 |
| Chen, YH | 1 |
| Loh, CH | 1 |
| Yang, T | 1 |
| Wu, TN | 1 |
| Hsieh, LL | 1 |
| Matsuoka, H | 1 |
| Narasimha, K | 1 |
| Nakajima, I | 1 |
| Koike, T | 1 |
| Hayashi, T | 1 |
| Honda, H | 3 |
| Fuchinoue, S | 3 |
| Teraoka, S | 3 |
| Agishi, T | 3 |
| Otaka, T | 1 |
| Riley, RJ | 1 |
| Alley, MC | 1 |
| Pacula-Cox, CM | 1 |
| Hursey, ML | 1 |
| Rubinstein, LR | 1 |
| Boyd, MR | 1 |
| Yamada, S | 1 |
| Oldham, RK | 1 |
| Vogelzang, NJ | 1 |
| Paterson, MC | 2 |
| Suga, T | 1 |
| Takahashi, Y | 1 |
| Ogino, T | 1 |
| Mai, M | 1 |
| Braunschweiger, PG | 1 |
| Jones, SA | 1 |
| Johnson, CS | 1 |
| Furmanski, P | 1 |
| Furukawa, T | 1 |
| Kubota, T | 1 |
| Suto, A | 1 |
| Takahara, T | 1 |
| Yamaguchi, H | 1 |
| Takeuchi, T | 1 |
| Kase, S | 1 |
| Kodaira, S | 1 |
| Ishibiki, K | 1 |
| Kitajima, M | 1 |
| Yamamoto, S | 1 |
| Hoon, DS | 1 |
| Chandler, P | 1 |
| Schmid, I | 1 |
| Irie, RF | 1 |
| Rotman, M | 1 |
| Aziz, H | 1 |
| Sinha, BK | 1 |
| Mimnaugh, EG | 1 |
| Yamaue, H | 1 |
| Tanimura, H | 1 |
| Terashita, S | 1 |
| Iwahashi, M | 1 |
| Tani, M | 1 |
| Tsunoda, T | 1 |
| Tamai, M | 1 |
| Ghose, T | 1 |
| Blair, AH | 1 |
| Kitamura, K | 1 |
| Noguchi, A | 1 |
| Takada, M | 1 |
| Fukuoka, M | 1 |
| Orr, D | 1 |
| Oldham, R | 1 |
| Lewis, M | 1 |
| Ogden, J | 1 |
| Liao, SK | 1 |
| Leung, K | 1 |
| Dupere, S | 1 |
| Birch, R | 1 |
| Avner, B | 1 |
| Kitsukawa, K | 1 |
| Taguchi, T | 3 |
| Ichino, Y | 1 |
| Ishikawa, T | 1 |
| Tsuji, H | 1 |
| Nakazawa, H | 2 |
| Okumura, T | 1 |
| Hirabayashi, N | 2 |
| Nosoh, Y | 1 |
| Yoshinaka, K | 1 |
| Yamaguchi, M | 2 |
| Niimoto, M | 2 |
| Matsumoto, T | 1 |
| Himeno, K | 1 |
| Mitani, M | 1 |
| Miake, S | 1 |
| Nomoto, K | 1 |
| Kurokawa, H | 1 |
| Kamita, N | 1 |
| Sasaki, K | 1 |
| Nagahori, J | 1 |
| Okazaki, M | 1 |
| Kijima, Y | 1 |
| Saito, H | 1 |
| Ritsuno, H | 1 |
| Yamaguchi, Y | 1 |
| Inaniwa, K | 1 |
| Karanes, C | 1 |
| Ratanatharathorn, V | 1 |
| Schilcher, RB | 1 |
| Young, JD | 1 |
| Emmer, D | 1 |
| Hoschner, JA | 1 |
| Leichman, L | 1 |
| Baker, LH | 1 |
| Woods, WG | 1 |
| Byrne, TD | 1 |
| Goto, T | 1 |
| Urata, A | 1 |
| Sugiura, T | 1 |
| Kerpel-Fronius, S | 1 |
| Stuurman, M | 2 |
| de Vries, J | 2 |
| Tsuchitani, T | 1 |
| Imai, S | 1 |
| Kan, N | 1 |
| Ohgaki, K | 1 |
| Tobe, T | 1 |
| Morimoto, M | 1 |
| Noso, Y | 1 |
| Niimi, K | 1 |
| Verwey, J | 1 |
| Lankelma, J | 1 |
| van Hoogenhuijze, J | 1 |
| van Bochove, A | 1 |
| Hattori, H | 1 |
| Mikuriya, S | 1 |
| Mamiya, T | 1 |
| Hatano, K | 1 |
| Shiina, T | 1 |
| Yamada, T | 1 |
| Funke-Küpper, AJ | 1 |
| Teule, GJ | 1 |
| Pardini, LL | 1 |
| Elliott, AJ | 1 |
| Pardini, RS | 1 |
| Miller, KJ | 1 |
| McGovern, RM | 1 |
| Ames, MM | 1 |
| Ensminger, WD | 1 |
| Gyves, JW | 1 |
| Stetson, P | 1 |
| Walker-Andrews, S | 1 |
| Grimm, EA | 1 |
| Wilson, DJ | 1 |
| Barybin, AS | 1 |
| Reshchikov, VP | 1 |
| Erlichman, C | 1 |
| Takahashi, K | 2 |
| Toma, H | 1 |
| Yokoyama, M | 1 |
| Takahashi, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Phase 1B Study for Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Oxaliplatin-based Chemotherapy in Patients With Gastro-intestinal Malignancies[NCT04729205] | Phase 1 | 9 participants (Actual) | Interventional | 2021-01-13 | Terminated (stopped due to Investigational drug not available) | ||
| A Phase I, Dose-Escalating, Safety Study of an Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PL-MLP, PROMITIL) in Cancer Patients With Solid Tumors.[NCT01705002] | Phase 1 | 88 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| A Phase II Study of 5-Fluorouracil Administered as a One Hour Infusion in Combination With Calcium Leucovorin and Interferon Alpha-2A in Advanced Colorectal Cancer[NCT00001428] | Phase 2 | 65 participants | Interventional | 1995-02-28 | Completed | ||
| The Effects of Exercise Training on Tumor Vascularity and Response to Neoadjuvant Therapy in Operable Breast Cancer: A Phase I-II Study[NCT00405678] | Phase 1/Phase 2 | 23 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
42 reviews available for mitomycin and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Development of Promitil®, a lipidic prodrug of mitomycin c in PEGylated liposomes: From bench to bedside.
Topics: Animals; Antibiotics, Antineoplastic; Humans; Lipids; Liposomes; Mitomycin; Neoplasms; Polyethylene | 2020 |
Development of Promitil®, a lipidic prodrug of mitomycin c in PEGylated liposomes: From bench to bedside.
Topics: Animals; Antibiotics, Antineoplastic; Humans; Lipids; Liposomes; Mitomycin; Neoplasms; Polyethylene | 2020 |
Molecular functions and cellular roles of the ChlR1 (DDX11) helicase defective in the rare cohesinopathy Warsaw breakage syndrome.
Topics: Abnormalities, Multiple; DEAD-box RNA Helicases; DNA Breaks; DNA Helicases; G-Quadruplexes; Genomic | 2014 |
Molecular functions and cellular roles of the ChlR1 (DDX11) helicase defective in the rare cohesinopathy Warsaw breakage syndrome.
Topics: Abnormalities, Multiple; DEAD-box RNA Helicases; DNA Breaks; DNA Helicases; G-Quadruplexes; Genomic | 2014 |
Antineoplastic agents and thrombotic microangiopathy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; H | 2017 |
Antineoplastic agents and thrombotic microangiopathy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; H | 2017 |
Gene therapy approaches to enhance bioreductive drug treatment.
Topics: Alkylating Agents; Animals; Anthraquinones; Breast Neoplasms; Cytochrome P-450 Enzyme System; Cytoch | 2008 |
Gene therapy approaches to enhance bioreductive drug treatment.
Topics: Alkylating Agents; Animals; Anthraquinones; Breast Neoplasms; Cytochrome P-450 Enzyme System; Cytoch | 2008 |
Fanconi anemia and its diagnosis.
Topics: Congenital Abnormalities; DNA Damage; Endocrine System Diseases; Epoxy Compounds; Fanconi Anemia; Ge | 2009 |
Fanconi anemia and its diagnosis.
Topics: Congenital Abnormalities; DNA Damage; Endocrine System Diseases; Epoxy Compounds; Fanconi Anemia; Ge | 2009 |
NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.
Topics: Antineoplastic Agents; Benzoquinones; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; | 2012 |
NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.
Topics: Antineoplastic Agents; Benzoquinones; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; | 2012 |
[Preface-importance of supportive therapies against adverse drug reactions in cancer treatment].
Topics: Anaphylaxis; Antineoplastic Agents; Bleomycin; Busulfan; Heart; Humans; Lung; Mitomycin; Neoplasms; | 2002 |
[Preface-importance of supportive therapies against adverse drug reactions in cancer treatment].
Topics: Anaphylaxis; Antineoplastic Agents; Bleomycin; Busulfan; Heart; Humans; Lung; Mitomycin; Neoplasms; | 2002 |
BIOCHEMISTRY OF CANCER (METABOLIC ASPECTS).
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Azaguanine; Azaserine; Carcinoma, Ehrlich Tum | 1963 |
BIOCHEMISTRY OF CANCER (METABOLIC ASPECTS).
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Azaguanine; Azaserine; Carcinoma, Ehrlich Tum | 1963 |
NEWER ANTICANCER AGENTS.
Topics: Alkylating Agents; Antineoplastic Agents; Arsenicals; Cyclophosphamide; Dactinomycin; Fluorouracil; | 1964 |
NEWER ANTICANCER AGENTS.
Topics: Alkylating Agents; Antineoplastic Agents; Arsenicals; Cyclophosphamide; Dactinomycin; Fluorouracil; | 1964 |
MECHANISMS OF RESISTANCE TO ANTICANCER AGENTS.
Topics: Alkylating Agents; Antineoplastic Agents; Azaserine; Dactinomycin; DNA; Drug Resistance; Drug Resist | 1963 |
MECHANISMS OF RESISTANCE TO ANTICANCER AGENTS.
Topics: Alkylating Agents; Antineoplastic Agents; Azaserine; Dactinomycin; DNA; Drug Resistance; Drug Resist | 1963 |
Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbon | 2004 |
Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbon | 2004 |
DT-diaphorase: a target for new anticancer drugs.
Topics: Antibiotics, Antineoplastic; Aziridines; Benzoquinones; Clinical Trials as Topic; Drug Resistance; G | 2004 |
DT-diaphorase: a target for new anticancer drugs.
Topics: Antibiotics, Antineoplastic; Aziridines; Benzoquinones; Clinical Trials as Topic; Drug Resistance; G | 2004 |
Bioreductive drugs: from concept to clinic.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Cell Hypoxia; Genetic Therapy; Humans; Mitomycin; Ne | 2007 |
Bioreductive drugs: from concept to clinic.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Cell Hypoxia; Genetic Therapy; Humans; Mitomycin; Ne | 2007 |
Macromolecule-drug conjugates in targeted cancer chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Antibodies, Neoplasm; Antineoplastic Agents; Blood Proteins; C | 1984 |
Macromolecule-drug conjugates in targeted cancer chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Antibodies, Neoplasm; Antineoplastic Agents; Blood Proteins; C | 1984 |
[Effect of chemotherapy on anticancer immune effector cells].
Topics: Animals; Antineoplastic Agents; Cell Division; Cytotoxicity, Immunologic; Humans; Immunity; Killer C | 1983 |
[Effect of chemotherapy on anticancer immune effector cells].
Topics: Animals; Antineoplastic Agents; Cell Division; Cytotoxicity, Immunologic; Humans; Immunity; Killer C | 1983 |
A review of systemic hyperthermia.
Topics: Antineoplastic Agents; Carmustine; Combined Modality Therapy; Humans; Hyperthermia, Induced; Mitomyc | 1984 |
A review of systemic hyperthermia.
Topics: Antineoplastic Agents; Carmustine; Combined Modality Therapy; Humans; Hyperthermia, Induced; Mitomyc | 1984 |
[Clinical application of microencapsulated antineoplastic agents].
Topics: Animals; Antibiotics, Antineoplastic; Capsules; Delayed-Action Preparations; Dogs; Embolization, The | 1982 |
[Clinical application of microencapsulated antineoplastic agents].
Topics: Animals; Antibiotics, Antineoplastic; Capsules; Delayed-Action Preparations; Dogs; Embolization, The | 1982 |
Xanthine dehydrogenase and its role in cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Biotransformation; Humans; Mitomycin; NAD(P)H Dehydrogenase (Quinone | 1994 |
Xanthine dehydrogenase and its role in cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Biotransformation; Humans; Mitomycin; NAD(P)H Dehydrogenase (Quinone | 1994 |
Mitomycin C: a prototype bioreductive agent.
Topics: Animals; Biotransformation; Cell Hypoxia; Clinical Trials as Topic; Combined Modality Therapy; Human | 1994 |
Mitomycin C: a prototype bioreductive agent.
Topics: Animals; Biotransformation; Cell Hypoxia; Clinical Trials as Topic; Combined Modality Therapy; Human | 1994 |
Cellular approaches to bioreductive drug mechanisms.
Topics: Animals; Antineoplastic Agents; CHO Cells; Cricetinae; Humans; Mitomycin; Neoplasms; Oxidation-Reduc | 1993 |
Cellular approaches to bioreductive drug mechanisms.
Topics: Animals; Antineoplastic Agents; CHO Cells; Cricetinae; Humans; Mitomycin; Neoplasms; Oxidation-Reduc | 1993 |
Mitomycins.
Topics: Animals; Antibiotics, Antineoplastic; Cell Hypoxia; Drug Resistance, Neoplasm; Drug Therapy, Combina | 1996 |
Mitomycins.
Topics: Animals; Antibiotics, Antineoplastic; Cell Hypoxia; Drug Resistance, Neoplasm; Drug Therapy, Combina | 1996 |
[Development of drug delivery systems for macromolecular drugs].
Topics: Antibiotics, Antineoplastic; Dextrans; DNA; Drug Delivery Systems; Drug Design; Macromolecular Subst | 1996 |
[Development of drug delivery systems for macromolecular drugs].
Topics: Antibiotics, Antineoplastic; Dextrans; DNA; Drug Delivery Systems; Drug Design; Macromolecular Subst | 1996 |
Combination chemotherapy studies with gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisp | 1997 |
Combination chemotherapy studies with gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisp | 1997 |
Enzymology of mitomycin C metabolic activation in tumour tissue: implications for enzyme-directed bioreductive drug development.
Topics: Antibiotics, Antineoplastic; Biotransformation; DNA; Humans; Mitomycin; NAD(P)H Dehydrogenase (Quino | 1998 |
Enzymology of mitomycin C metabolic activation in tumour tissue: implications for enzyme-directed bioreductive drug development.
Topics: Antibiotics, Antineoplastic; Biotransformation; DNA; Humans; Mitomycin; NAD(P)H Dehydrogenase (Quino | 1998 |
[Combination chemotherapy--present status and problems].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclopho | 1999 |
[Combination chemotherapy--present status and problems].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclopho | 1999 |
Clinical applications of quinone-containing alkylating agents.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Aziridines; B | 2000 |
Clinical applications of quinone-containing alkylating agents.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Aziridines; B | 2000 |
[From cancer prevention to cancer treatment].
Topics: Animals; Antineoplastic Agents; Benzoates; Bleomycin; Carcinogens; Dibenzazepines; Food Analysis; Hu | 2000 |
[From cancer prevention to cancer treatment].
Topics: Animals; Antineoplastic Agents; Benzoates; Bleomycin; Carcinogens; Dibenzazepines; Food Analysis; Hu | 2000 |
ATP depletion + pyrimidine depletion can markedly enhance cancer therapy: fresh insight for a new approach.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Survival; Ci | 2000 |
ATP depletion + pyrimidine depletion can markedly enhance cancer therapy: fresh insight for a new approach.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Survival; Ci | 2000 |
Mitomycin C: a clinical update.
Topics: Antibiotics, Antineoplastic; Clinical Trials as Topic; Humans; Mitomycin; Neoplasms | 2001 |
Mitomycin C: a clinical update.
Topics: Antibiotics, Antineoplastic; Clinical Trials as Topic; Humans; Mitomycin; Neoplasms | 2001 |
DT-diaphorase and cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Aziridines; Benzoquinones; Dihydrolipoamide Dehydrogenase; Drug Desi | 1992 |
DT-diaphorase and cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Aziridines; Benzoquinones; Dihydrolipoamide Dehydrogenase; Drug Desi | 1992 |
Nephrotoxicity from chemotherapy: prevention and management.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Gallium; Humans; Ifosfamide; Kidney Diseases; Methotr | 1991 |
Nephrotoxicity from chemotherapy: prevention and management.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Gallium; Humans; Ifosfamide; Kidney Diseases; Methotr | 1991 |
Mitomycin C.
Topics: Animals; Combined Modality Therapy; Humans; Mitomycin; Neoplasms | 1991 |
Mitomycin C.
Topics: Animals; Combined Modality Therapy; Humans; Mitomycin; Neoplasms | 1991 |
Concomitant continuous infusion chemotherapy and radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Combined Modali | 1990 |
Concomitant continuous infusion chemotherapy and radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Combined Modali | 1990 |
Free radicals and anticancer drug resistance: oxygen free radicals in the mechanisms of drug cytotoxicity and resistance by certain tumors.
Topics: Animals; Antineoplastic Agents; Doxorubicin; Drug Resistance; Free Radicals; Humans; Mitomycin; Mito | 1990 |
Free radicals and anticancer drug resistance: oxygen free radicals in the mechanisms of drug cytotoxicity and resistance by certain tumors.
Topics: Animals; Antineoplastic Agents; Doxorubicin; Drug Resistance; Free Radicals; Humans; Mitomycin; Mito | 1990 |
Mitomycin C: mechanism of action, usefulness and limitations.
Topics: Animals; Humans; Mitomycin; Neoplasms | 1990 |
Mitomycin C: mechanism of action, usefulness and limitations.
Topics: Animals; Humans; Mitomycin; Neoplasms | 1990 |
The design of cytotoxic-agent-antibody conjugates.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibody Specificity; Antigens, Neoplasm; Bleom | 1987 |
The design of cytotoxic-agent-antibody conjugates.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibody Specificity; Antigens, Neoplasm; Bleom | 1987 |
[Treatment of malignant pleural effusion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Instillation, Drug; Interleukin | 1989 |
[Treatment of malignant pleural effusion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Instillation, Drug; Interleukin | 1989 |
[Advances in mitomycin studies--clinical studies: progress over 10 years].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Humans; Infusions, Intraveno | 1987 |
[Advances in mitomycin studies--clinical studies: progress over 10 years].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Humans; Infusions, Intraveno | 1987 |
[Recent advanced studies on mitomycins, antitumor activity and mode of action].
Topics: Animals; Cell Line; Colonic Neoplasms; Humans; Leukemia P388; Mitomycin; Mitomycins; Neoplasms; Panc | 1987 |
[Recent advanced studies on mitomycins, antitumor activity and mode of action].
Topics: Animals; Cell Line; Colonic Neoplasms; Humans; Leukemia P388; Mitomycin; Mitomycins; Neoplasms; Panc | 1987 |
[Use of permanent magnets and magnetic fluids in experimental oncology].
Topics: Albumins; Animals; Antineoplastic Agents; Doxorubicin; Humans; Hyperthermia, Induced; Magnetics; Mic | 1985 |
[Use of permanent magnets and magnetic fluids in experimental oncology].
Topics: Albumins; Animals; Antineoplastic Agents; Doxorubicin; Humans; Hyperthermia, Induced; Magnetics; Mic | 1985 |
25 trials available for mitomycin and Neoplasms
| Article | Year |
|---|---|
Pegylated Liposomal Mitomycin C Lipidic Prodrug in Combination With External Beam Radiation Therapy in Patients With Advanced Cancer: A Phase 1B Study.
Topics: Humans; Lipids; Mitomycin; Neoplasms; Neutropenia; Polyethylene Glycols; Prodrugs | 2023 |
Pegylated Liposomal Mitomycin C Lipidic Prodrug in Combination With External Beam Radiation Therapy in Patients With Advanced Cancer: A Phase 1B Study.
Topics: Humans; Lipids; Mitomycin; Neoplasms; Neutropenia; Polyethylene Glycols; Prodrugs | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Fatigue; Female; Humans; Liposomes; Male; Maximum | 2015 |
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Fatigue; Female; Humans; Liposomes; Male; Maximum | 2015 |
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Fatigue; Female; Humans; Liposomes; Male; Maximum | 2015 |
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Fatigue; Female; Humans; Liposomes; Male; Maximum | 2015 |
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Fatigue; Female; Humans; Liposomes; Male; Maximum | 2015 |
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Fatigue; Female; Humans; Liposomes; Male; Maximum | 2015 |
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Fatigue; Female; Humans; Liposomes; Male; Maximum | 2015 |
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Fatigue; Female; Humans; Liposomes; Male; Maximum | 2015 |
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; | 2016 |
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; | 2016 |
Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celeco | 2009 |
Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celeco | 2009 |
Combination therapy with mitomycin C (NSC-26980), 5-fluorouracil (NSC-19893), and cytosine arabinoside (NSC-63878) for advanced cancer in man.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Colorectal | 1972 |
Combination therapy with mitomycin C (NSC-26980), 5-fluorouracil (NSC-19893), and cytosine arabinoside (NSC-63878) for advanced cancer in man.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Colorectal | 1972 |
Chronic anemia due to mitomycin C is drug dose-dependent, normocytic, progressive, related to erythropoietin levels and quantitatively predictable: implications for radiochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Chemoradiotherapy; Chronic Disease; D | 2011 |
Chronic anemia due to mitomycin C is drug dose-dependent, normocytic, progressive, related to erythropoietin levels and quantitatively predictable: implications for radiochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Chemoradiotherapy; Chronic Disease; D | 2011 |
B ultrasound-guided hyperthermic intraperitoneal perfusion chemotherapy for the treatment of malignant ascites.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Chemotherapy, Cancer, Regional Perfus | 2012 |
B ultrasound-guided hyperthermic intraperitoneal perfusion chemotherapy for the treatment of malignant ascites.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Chemotherapy, Cancer, Regional Perfus | 2012 |
Mitomycin as a modulator of irinotecan anticancer activity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Dose-Response Relation | 2002 |
Mitomycin as a modulator of irinotecan anticancer activity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Dose-Response Relation | 2002 |
Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Di | 2007 |
Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Di | 2007 |
Macromolecule-drug conjugates in targeted cancer chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Antibodies, Neoplasm; Antineoplastic Agents; Blood Proteins; C | 1984 |
Macromolecule-drug conjugates in targeted cancer chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Antibodies, Neoplasm; Antineoplastic Agents; Blood Proteins; C | 1984 |
[Clinical studies on induced hypertension chemotherapy based on functional characteristics of microcirculation of tumor vessels].
Topics: Angiotensin II; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Doxorubicin | 1984 |
[Clinical studies on induced hypertension chemotherapy based on functional characteristics of microcirculation of tumor vessels].
Topics: Angiotensin II; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Doxorubicin | 1984 |
[Clinical evaluation of various antineoplastic agents combined with urokinase--a comparison between urokinase from tissue culture (TCUK) and urine-derived urokinase (UUK)].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Clinical Trials a | 1982 |
[Clinical evaluation of various antineoplastic agents combined with urokinase--a comparison between urokinase from tissue culture (TCUK) and urine-derived urokinase (UUK)].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Clinical Trials a | 1982 |
Phase I study of mitomycin C and menadione in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Erythrocytes; Female; Glucosephosphate | 1995 |
Phase I study of mitomycin C and menadione in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Erythrocytes; Female; Glucosephosphate | 1995 |
Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biotransformation; Bone Marrow Diseases; Carcino | 1995 |
Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biotransformation; Bone Marrow Diseases; Carcino | 1995 |
Laboratory correlates of chemoimmunotherapy with low-dose recombinant interleukin-2 and mitomycin C in patients with advanced carcinoma.
Topics: Adult; Aged; Cell Adhesion; Combined Modality Therapy; Cytokines; Cytotoxicity, Immunologic; Dose-Re | 1994 |
Laboratory correlates of chemoimmunotherapy with low-dose recombinant interleukin-2 and mitomycin C in patients with advanced carcinoma.
Topics: Adult; Aged; Cell Adhesion; Combined Modality Therapy; Cytokines; Cytotoxicity, Immunologic; Dose-Re | 1994 |
A phase I study of the left-shifting agent BW12C79 plus mitomycin C and the effect on the skeletal muscle metabolism using 31P magnetic resonance spectroscopy.
Topics: Adult; Aged; Benzaldehydes; Drug Therapy, Combination; Female; Hemoglobins; Humans; Magnetic Resonan | 1993 |
A phase I study of the left-shifting agent BW12C79 plus mitomycin C and the effect on the skeletal muscle metabolism using 31P magnetic resonance spectroscopy.
Topics: Adult; Aged; Benzaldehydes; Drug Therapy, Combination; Female; Hemoglobins; Humans; Magnetic Resonan | 1993 |
Tumor necrosis factor administration is associated with increased endogenous production of M-CSF and G-CSF but not GM-CSF in human cancer patients.
Topics: Colonic Neoplasms; Fibroma; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Sti | 1996 |
Tumor necrosis factor administration is associated with increased endogenous production of M-CSF and G-CSF but not GM-CSF in human cancer patients.
Topics: Colonic Neoplasms; Fibroma; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Sti | 1996 |
Phase I study of the mitomycin C analogue BMS-181174.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Female; Heart; Humans; Kidney; Lung; Male; Middle Ag | 1998 |
Phase I study of the mitomycin C analogue BMS-181174.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Female; Heart; Humans; Kidney; Lung; Male; Middle Ag | 1998 |
Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Dose-Response Relationship, Drug; | 1999 |
Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Dose-Response Relationship, Drug; | 1999 |
Phase I bioequivalency study of MitoExtra and mitomycin C in patients with solid tumors.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; beta-Cyclo | 2001 |
Phase I bioequivalency study of MitoExtra and mitomycin C in patients with solid tumors.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; beta-Cyclo | 2001 |
[Dose-intensive chemotherapy with continuous infusion 5-fluorouracil].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined | 1999 |
[Dose-intensive chemotherapy with continuous infusion 5-fluorouracil].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined | 1999 |
Clinical aspects of drug delivery to tumors.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Deliver | 2002 |
Clinical aspects of drug delivery to tumors.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Deliver | 2002 |
Custom-tailored drug immunoconjugates in cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Neoplasm; Doxorubicin; Female; Flow Cytometry; Humans; Immunohis | 1991 |
Custom-tailored drug immunoconjugates in cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Neoplasm; Doxorubicin; Female; Flow Cytometry; Humans; Immunohis | 1991 |
Concomitant continuous infusion chemotherapy and radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Combined Modali | 1990 |
Concomitant continuous infusion chemotherapy and radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Combined Modali | 1990 |
223 other studies available for mitomycin and Neoplasms
| Article | Year |
|---|---|
Potent antitumor bifunctional DNA alkylating agents, synthesis and biological activities of 3a-aza-cyclopenta[a]indenes.
Topics: Animals; Antineoplastic Agents, Alkylating; Aza Compounds; Breast Neoplasms; Carcinoma; Cell Cycle; | 2009 |
Potent antitumor bifunctional DNA alkylating agents, synthesis and biological activities of 3a-aza-cyclopenta[a]indenes.
Topics: Animals; Antineoplastic Agents, Alkylating; Aza Compounds; Breast Neoplasms; Carcinoma; Cell Cycle; | 2009 |
Solvent free synthesis, anti-inflammatory and anticancer activity evaluation of tricyclic and tetracyclic benzimidazole derivatives.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; | 2010 |
Solvent free synthesis, anti-inflammatory and anticancer activity evaluation of tricyclic and tetracyclic benzimidazole derivatives.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; | 2010 |
2,5-Disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Cell Proliferation; Drug Design; Drug Eval | 2011 |
2,5-Disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Cell Proliferation; Drug Design; Drug Eval | 2011 |
Synthesis, antiproliferative activity and genotoxicity of novel anthracene-containing aminophosphonates and a new anthracene-derived Schiff base.
Topics: Animals; Anthracenes; Antineoplastic Agents; Cell Line; Cell Proliferation; Drug Screening Assays, A | 2012 |
Synthesis, antiproliferative activity and genotoxicity of novel anthracene-containing aminophosphonates and a new anthracene-derived Schiff base.
Topics: Animals; Anthracenes; Antineoplastic Agents; Cell Line; Cell Proliferation; Drug Screening Assays, A | 2012 |
Bakuchiol derivatives as novel and potent cytotoxic agents: a report.
Topics: Antineoplastic Agents, Phytogenic; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; DNA | 2012 |
Bakuchiol derivatives as novel and potent cytotoxic agents: a report.
Topics: Antineoplastic Agents, Phytogenic; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; DNA | 2012 |
Combining PEGylated mito-atovaquone with MCT and Krebs cycle redox inhibitors as a potential strategy to abrogate tumor cell proliferation.
Topics: Antineoplastic Agents; Atovaquone; Cell Line, Tumor; Cell Proliferation; Citric Acid Cycle; Electron | 2022 |
Combining PEGylated mito-atovaquone with MCT and Krebs cycle redox inhibitors as a potential strategy to abrogate tumor cell proliferation.
Topics: Antineoplastic Agents; Atovaquone; Cell Line, Tumor; Cell Proliferation; Citric Acid Cycle; Electron | 2022 |
Radiation Therapies in Cancer.
Topics: Gemcitabine; Humans; Immunotherapy; Mitomycin; Neoplasms; Nimorazole | 2023 |
Radiation Therapies in Cancer.
Topics: Gemcitabine; Humans; Immunotherapy; Mitomycin; Neoplasms; Nimorazole | 2023 |
Revisiting the Radical Radiotherapy-Radiochemotherapy Results in Anal Canal Cancers: (TROD Gastrointestinal Group Study 02-005).
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Disea | 2023 |
Revisiting the Radical Radiotherapy-Radiochemotherapy Results in Anal Canal Cancers: (TROD Gastrointestinal Group Study 02-005).
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Disea | 2023 |
Successful use of topical mitomycin C for the treatment of a putative neoplastic vascular mass on the nictitating membrane of a dog.
Topics: Administration, Topical; Animals; Antibiotics, Antineoplastic; Dog Diseases; Dogs; Female; Mitomycin | 2020 |
Successful use of topical mitomycin C for the treatment of a putative neoplastic vascular mass on the nictitating membrane of a dog.
Topics: Administration, Topical; Animals; Antibiotics, Antineoplastic; Dog Diseases; Dogs; Female; Mitomycin | 2020 |
Intrinsic growth heterogeneity of mouse leukemia cells underlies differential susceptibility to a growth-inhibiting anticancer drug.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Leu | 2021 |
Intrinsic growth heterogeneity of mouse leukemia cells underlies differential susceptibility to a growth-inhibiting anticancer drug.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Leu | 2021 |
Comprehensive Mutational Analysis of the BRCA1-Associated DNA Helicase and Tumor-Suppressor FANCJ/BACH1/BRIP1.
Topics: BRCA1 Protein; Cell Line, Tumor; Cisplatin; Codon, Nonsense; Cross-Linking Reagents; DNA Helicases; | 2021 |
Comprehensive Mutational Analysis of the BRCA1-Associated DNA Helicase and Tumor-Suppressor FANCJ/BACH1/BRIP1.
Topics: BRCA1 Protein; Cell Line, Tumor; Cisplatin; Codon, Nonsense; Cross-Linking Reagents; DNA Helicases; | 2021 |
No Good Deed Goes Unpunished: Mitomycin-Induced Pulmonary Venoocclusive Disease and Cancer.
Topics: Humans; Mitomycin; Neoplasms; Pulmonary Veno-Occlusive Disease | 2021 |
No Good Deed Goes Unpunished: Mitomycin-Induced Pulmonary Venoocclusive Disease and Cancer.
Topics: Humans; Mitomycin; Neoplasms; Pulmonary Veno-Occlusive Disease | 2021 |
Metformin alters therapeutic effects in the BALB/c tumor therapy model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BALB 3T3 Cells; Carcinogens; Cell Survival; | 2021 |
Metformin alters therapeutic effects in the BALB/c tumor therapy model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BALB 3T3 Cells; Carcinogens; Cell Survival; | 2021 |
Smart activatable and traceable dual-prodrug for image-guided combination photodynamic and chemo-therapy.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line; Cell Line, Tumor; Fluorescence; Glutathione; Humans | 2017 |
Smart activatable and traceable dual-prodrug for image-guided combination photodynamic and chemo-therapy.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line; Cell Line, Tumor; Fluorescence; Glutathione; Humans | 2017 |
Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Anima | 2017 |
Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Anima | 2017 |
RUNX Poly(ADP-Ribosyl)ation and BLM Interaction Facilitate the Fanconi Anemia Pathway of DNA Repair.
Topics: Animals; Chlorocebus aethiops; Chromatin; Core Binding Factor Alpha 2 Subunit; Core Binding Factor A | 2018 |
RUNX Poly(ADP-Ribosyl)ation and BLM Interaction Facilitate the Fanconi Anemia Pathway of DNA Repair.
Topics: Animals; Chlorocebus aethiops; Chromatin; Core Binding Factor Alpha 2 Subunit; Core Binding Factor A | 2018 |
Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cisplatin; DNA Breaks, Double-Stranded; DNA Rep | 2013 |
Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cisplatin; DNA Breaks, Double-Stranded; DNA Rep | 2013 |
A high-throughput yeast assay identifies synergistic drug combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Survival; Drug | 2013 |
A high-throughput yeast assay identifies synergistic drug combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Survival; Drug | 2013 |
Inhibitory effects of marine-derived DNA-binding anti-tumour tetrahydroisoquinolines on the Fanconi anaemia pathway.
Topics: Animals; Antineoplastic Agents; Binding Sites; Carbolines; Cell Line, Tumor; Dioxoles; DNA; Dose-Res | 2013 |
Inhibitory effects of marine-derived DNA-binding anti-tumour tetrahydroisoquinolines on the Fanconi anaemia pathway.
Topics: Animals; Antineoplastic Agents; Binding Sites; Carbolines; Cell Line, Tumor; Dioxoles; DNA; Dose-Res | 2013 |
Targeting an Achilles' heel of cancer with a WRN helicase inhibitor.
Topics: Cell Line; DNA End-Joining Repair; Enzyme Inhibitors; Fanconi Anemia; Humans; Maleimides; Mitomycin; | 2013 |
Targeting an Achilles' heel of cancer with a WRN helicase inhibitor.
Topics: Cell Line; DNA End-Joining Repair; Enzyme Inhibitors; Fanconi Anemia; Humans; Maleimides; Mitomycin; | 2013 |
In vitro anti cancer activity of ethanol extract fractions of Aerva lanata L.
Topics: Acetates; Amaranthaceae; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Ch | 2013 |
In vitro anti cancer activity of ethanol extract fractions of Aerva lanata L.
Topics: Acetates; Amaranthaceae; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Ch | 2013 |
In vitro cytotoxic and anticlastogenic activities of saxifragifolin B and cyclamin isolated from Cyclamen persicum and Cyclamen libanoticum.
Topics: Animals; Antibiotics, Antineoplastic; Antimutagenic Agents; Antineoplastic Agents, Phytogenic; Antio | 2014 |
In vitro cytotoxic and anticlastogenic activities of saxifragifolin B and cyclamin isolated from Cyclamen persicum and Cyclamen libanoticum.
Topics: Animals; Antibiotics, Antineoplastic; Antimutagenic Agents; Antineoplastic Agents, Phytogenic; Antio | 2014 |
[Antitumor antibiotics].
Topics: Antibiotics, Antineoplastic; Bleomycin; Dactinomycin; Humans; Mitomycin; Neoplasms; Peplomycin | 2015 |
[Antitumor antibiotics].
Topics: Antibiotics, Antineoplastic; Bleomycin; Dactinomycin; Humans; Mitomycin; Neoplasms; Peplomycin | 2015 |
Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Survival; Cholesterol; Female; Folic Ac | 2016 |
Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Survival; Cholesterol; Female; Folic Ac | 2016 |
Experimental evidence for killing the resistant cells and raising the efficacy and decreasing the toxicity of cytostatics and irradiation by mixtures of the agents of the passive antitumor defense system in the case of various tumor and normal cell lines
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line | 2009 |
Experimental evidence for killing the resistant cells and raising the efficacy and decreasing the toxicity of cytostatics and irradiation by mixtures of the agents of the passive antitumor defense system in the case of various tumor and normal cell lines
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line | 2009 |
Acetaldehyde stimulates FANCD2 monoubiquitination, H2AX phosphorylation, and BRCA1 phosphorylation in human cells in vitro: implications for alcohol-related carcinogenesis.
Topics: Acetaldehyde; Alcohol Drinking; BRCA1 Protein; Cell Line; Cross-Linking Reagents; DNA Damage; Ethano | 2009 |
Acetaldehyde stimulates FANCD2 monoubiquitination, H2AX phosphorylation, and BRCA1 phosphorylation in human cells in vitro: implications for alcohol-related carcinogenesis.
Topics: Acetaldehyde; Alcohol Drinking; BRCA1 Protein; Cell Line; Cross-Linking Reagents; DNA Damage; Ethano | 2009 |
Chemotherapy induces ATP release from tumor cells.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; Cadmium; Cell Line, Tumor; Cispla | 2009 |
Chemotherapy induces ATP release from tumor cells.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; Cadmium; Cell Line, Tumor; Cispla | 2009 |
Hepatobiliary procedures in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Diseases; Chemotherapy, Cancer, Regional P | 2011 |
Hepatobiliary procedures in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Diseases; Chemotherapy, Cancer, Regional P | 2011 |
2A peptide-based, lentivirus-mediated anti-death receptor 5 chimeric antibody expression prevents tumor growth in nude mice.
Topics: Animals; Antibodies, Monoclonal; Antibody Affinity; Cell Death; Disease Models, Animal; Drug Synergi | 2012 |
2A peptide-based, lentivirus-mediated anti-death receptor 5 chimeric antibody expression prevents tumor growth in nude mice.
Topics: Animals; Antibodies, Monoclonal; Antibody Affinity; Cell Death; Disease Models, Animal; Drug Synergi | 2012 |
Functional hyper-IL-6 from vaccinia virus-colonized tumors triggers platelet formation and helps to alleviate toxicity of mitomycin C enhanced virus therapy.
Topics: Animals; Blood Platelets; Cell Line, Tumor; Combined Modality Therapy; Female; Gene Expression; Huma | 2012 |
Functional hyper-IL-6 from vaccinia virus-colonized tumors triggers platelet formation and helps to alleviate toxicity of mitomycin C enhanced virus therapy.
Topics: Animals; Blood Platelets; Cell Line, Tumor; Combined Modality Therapy; Female; Gene Expression; Huma | 2012 |
Chemotherapy-induced toxicity is highly heritable in Drosophila melanogaster.
Topics: Animals; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drosophila melanogaster; Drug | 2012 |
Chemotherapy-induced toxicity is highly heritable in Drosophila melanogaster.
Topics: Animals; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drosophila melanogaster; Drug | 2012 |
[Not available, cope with it: an unacceptable scandal].
Topics: Adaptation, Psychological; Antineoplastic Agents; Commerce; Drug Industry; Health Services Accessibi | 2012 |
[Not available, cope with it: an unacceptable scandal].
Topics: Adaptation, Psychological; Antineoplastic Agents; Commerce; Drug Industry; Health Services Accessibi | 2012 |
Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activation.
Topics: Analysis of Variance; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; | 2012 |
Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activation.
Topics: Analysis of Variance; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; | 2012 |
Preclinical antitumor activity of a nanoparticulate SN38.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Proliferation; Female; H | 2013 |
Preclinical antitumor activity of a nanoparticulate SN38.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Proliferation; Female; H | 2013 |
Development and clinical application of drug delivery systems for cancer treatment.
Topics: Aged; Antineoplastic Agents; Carbon; Combined Modality Therapy; Drug Delivery Systems; Emulsions; Fe | 2002 |
Development and clinical application of drug delivery systems for cancer treatment.
Topics: Aged; Antineoplastic Agents; Carbon; Combined Modality Therapy; Drug Delivery Systems; Emulsions; Fe | 2002 |
Mathematical modelling of drug transport in tumour multicell spheroids and monolayer cultures.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Death; Computer Simulation; Dose-Response Relations | 2003 |
Mathematical modelling of drug transport in tumour multicell spheroids and monolayer cultures.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Death; Computer Simulation; Dose-Response Relations | 2003 |
Dendritic cells coinjected with tumor cells treated with an anticancer drug to induce tumor rejection.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Cytotoxicity Tests, Immunologic; Dendritic Cells; F | 2003 |
Dendritic cells coinjected with tumor cells treated with an anticancer drug to induce tumor rejection.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Cytotoxicity Tests, Immunologic; Dendritic Cells; F | 2003 |
The effect of mitomycin C on the growth of a variety of rat and mouse tumors.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antineoplastic Agents; Mice; Mitomycin; | 1958 |
The effect of mitomycin C on the growth of a variety of rat and mouse tumors.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antineoplastic Agents; Mice; Mitomycin; | 1958 |
Studies in a tumor spectrum. VIII. The effect of mitomycin C on the growth of a variety of mouse, rat, and hamster tumors.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Mice; Mitomycin; Neoplasms; Rats | 1959 |
Studies in a tumor spectrum. VIII. The effect of mitomycin C on the growth of a variety of mouse, rat, and hamster tumors.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Mice; Mitomycin; Neoplasms; Rats | 1959 |
A novel method for modification of tumor cells with bacterial superantigen with a heterobifunctional cross-linking agent in immunotherapy of cancer.
Topics: Animals; Antibodies; Cancer Vaccines; Cell Line, Tumor; Coculture Techniques; Cross-Linking Reagents | 2003 |
A novel method for modification of tumor cells with bacterial superantigen with a heterobifunctional cross-linking agent in immunotherapy of cancer.
Topics: Animals; Antibodies; Cancer Vaccines; Cell Line, Tumor; Coculture Techniques; Cross-Linking Reagents | 2003 |
[Experiences in the use of mitomycin C in the field of otolaryngology].
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Laryngeal Neoplasms; Larynx; Maxilla; Mitomycin; Neopl | 1961 |
[Experiences in the use of mitomycin C in the field of otolaryngology].
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Laryngeal Neoplasms; Larynx; Maxilla; Mitomycin; Neopl | 1961 |
[On the effect of carcinophylline and mitomycin C on the respiration and glycolysis of tumor cells].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antineoplastic Agents; Dermatologic Agents; Glyc | 1960 |
[On the effect of carcinophylline and mitomycin C on the respiration and glycolysis of tumor cells].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antineoplastic Agents; Dermatologic Agents; Glyc | 1960 |
Experimental combination treatment of disseminated cancer, in man, with mitomycin C, "Ayulo's filtrate," prednisolone, and/or androgen.
Topics: Androgens; Anti-Bacterial Agents; Antineoplastic Agents; Mitomycin; Neoplasms; Prednisolone; Therapi | 1961 |
Experimental combination treatment of disseminated cancer, in man, with mitomycin C, "Ayulo's filtrate," prednisolone, and/or androgen.
Topics: Androgens; Anti-Bacterial Agents; Antineoplastic Agents; Mitomycin; Neoplasms; Prednisolone; Therapi | 1961 |
[On the anti-proliferative and anti-tumor activity of mytomycin C].
Topics: Humans; Mitomycin; Neomycin; Neoplasms | 1961 |
[On the anti-proliferative and anti-tumor activity of mytomycin C].
Topics: Humans; Mitomycin; Neomycin; Neoplasms | 1961 |
Cancer chemotherapy (mitomycin-C) followed by bone marrow transplantation: improved administration associated with clamping of superior mesenteric and splenic arteries.
Topics: Antineoplastic Agents; Bone Marrow; Bone Marrow Transplantation; Constriction; Humans; Mesenteric Ar | 1962 |
Cancer chemotherapy (mitomycin-C) followed by bone marrow transplantation: improved administration associated with clamping of superior mesenteric and splenic arteries.
Topics: Antineoplastic Agents; Bone Marrow; Bone Marrow Transplantation; Constriction; Humans; Mesenteric Ar | 1962 |
A mitomycin C-resistant Jensen rat sarcoma: isolation and transplantation studies.
Topics: Animals; Mitomycin; Mitomycins; Neoplasms; Rats; Sarcoma; Sarcoma, Experimental | 1962 |
A mitomycin C-resistant Jensen rat sarcoma: isolation and transplantation studies.
Topics: Animals; Mitomycin; Mitomycins; Neoplasms; Rats; Sarcoma; Sarcoma, Experimental | 1962 |
[Radiation therapy combined with mitomycin C].
Topics: Humans; Mitomycin; Mitomycins; Neoplasms; Radiotherapy | 1962 |
[Radiation therapy combined with mitomycin C].
Topics: Humans; Mitomycin; Mitomycins; Neoplasms; Radiotherapy | 1962 |
Chemotherapy of malignant disease. I. Solid tumours.
Topics: Cyclophosphamide; Dactinomycin; Fluorouracil; Mechlorethamine; Methotrexate; Mitomycin; Mitomycins; | 1962 |
Chemotherapy of malignant disease. I. Solid tumours.
Topics: Cyclophosphamide; Dactinomycin; Fluorouracil; Mechlorethamine; Methotrexate; Mitomycin; Mitomycins; | 1962 |
[Current status of the chemotherapy of cancer in Japan].
Topics: Antineoplastic Agents; Humans; Japan; Mitomycin; Mitomycins; Neoplasms | 1962 |
[Current status of the chemotherapy of cancer in Japan].
Topics: Antineoplastic Agents; Humans; Japan; Mitomycin; Mitomycins; Neoplasms | 1962 |
Experimental treatment of cancer with mitomycin C alone or in combination with carzinophilin.
Topics: Antimicrobial Cationic Peptides; Antineoplastic Agents; Carcinoma; Humans; Mitomycin; Neoplasms; Pep | 1961 |
Experimental treatment of cancer with mitomycin C alone or in combination with carzinophilin.
Topics: Antimicrobial Cationic Peptides; Antineoplastic Agents; Carcinoma; Humans; Mitomycin; Neoplasms; Pep | 1961 |
[BASIC AND CLINICAL INVESTIGATION OF CANCER CHEMOTHERAPY].
Topics: Adolescent; Antineoplastic Agents; Child; Cyclophosphamide; Geriatrics; Infant; Mitomycin; Mitomycin | 1962 |
[BASIC AND CLINICAL INVESTIGATION OF CANCER CHEMOTHERAPY].
Topics: Adolescent; Antineoplastic Agents; Child; Cyclophosphamide; Geriatrics; Infant; Mitomycin; Mitomycin | 1962 |
OSTEOGENIC SARCOMA IN CHILDHOOD.
Topics: Adolescent; Bone Neoplasms; Child; Humans; Infant; Methotrexate; Mitomycin; Mitomycins; Neoplasms; O | 1963 |
OSTEOGENIC SARCOMA IN CHILDHOOD.
Topics: Adolescent; Bone Neoplasms; Child; Humans; Infant; Methotrexate; Mitomycin; Mitomycins; Neoplasms; O | 1963 |
A MITOMYCIN C-RESISTANT JENSEN RAT SARCOMA: CHEMOTHERAPY STUDIES.
Topics: Animals; Antineoplastic Agents; Mitomycin; Mitomycins; Neoplasms; Neoplasms, Experimental; Pharmacol | 1963 |
A MITOMYCIN C-RESISTANT JENSEN RAT SARCOMA: CHEMOTHERAPY STUDIES.
Topics: Animals; Antineoplastic Agents; Mitomycin; Mitomycins; Neoplasms; Neoplasms, Experimental; Pharmacol | 1963 |
[TREATMENTS OF LEUKOPENIA ASSOCIATED WITH THE THERAPY OF MALIGNANT TUMORS].
Topics: Anemia; Anemia, Aplastic; Antineoplastic Agents; Bone Marrow Transplantation; Japan; Leukocyte Count | 1963 |
[TREATMENTS OF LEUKOPENIA ASSOCIATED WITH THE THERAPY OF MALIGNANT TUMORS].
Topics: Anemia; Anemia, Aplastic; Antineoplastic Agents; Bone Marrow Transplantation; Japan; Leukocyte Count | 1963 |
[CLINICAL AND EXPERIMENTAL STUDIES ON CHANGES IN THE BODY FLUIDS IN CANCER].
Topics: Antineoplastic Agents; Arginine; Ascites; Aspartate Aminotransferases; Blood Chemical Analysis; Bloo | 1963 |
[CLINICAL AND EXPERIMENTAL STUDIES ON CHANGES IN THE BODY FLUIDS IN CANCER].
Topics: Antineoplastic Agents; Arginine; Ascites; Aspartate Aminotransferases; Blood Chemical Analysis; Bloo | 1963 |
[CLINICAL RESULTS WITH MITOMYCIN C].
Topics: Injections; Injections, Intravenous; Mitomycin; Mitomycins; Neoplasms; Toxicology | 1963 |
[CLINICAL RESULTS WITH MITOMYCIN C].
Topics: Injections; Injections, Intravenous; Mitomycin; Mitomycins; Neoplasms; Toxicology | 1963 |
THE IN VITRO INDUCTION OF DRUG RESISTANCE OF YOSHIDA SARCOMA TO ANTITUMOR AGENTS.
Topics: Animals; Antineoplastic Agents; DNA; DNA, Neoplasm; Drug Resistance; In Vitro Techniques; Mechloreth | 1963 |
THE IN VITRO INDUCTION OF DRUG RESISTANCE OF YOSHIDA SARCOMA TO ANTITUMOR AGENTS.
Topics: Animals; Antineoplastic Agents; DNA; DNA, Neoplasm; Drug Resistance; In Vitro Techniques; Mechloreth | 1963 |
EARLY RESULTS OF COMBINED RADIATION AND CHEMOTHERAPY IN TREATMENT OF MALIGNANT TUMORS.
Topics: Antineoplastic Agents; Colonic Neoplasms; Dactinomycin; Fluorouracil; Humans; Lung Neoplasms; Mitomy | 1963 |
EARLY RESULTS OF COMBINED RADIATION AND CHEMOTHERAPY IN TREATMENT OF MALIGNANT TUMORS.
Topics: Antineoplastic Agents; Colonic Neoplasms; Dactinomycin; Fluorouracil; Humans; Lung Neoplasms; Mitomy | 1963 |
SIDE-EFFECTS OF COMBINED RADIATION AND CHEMOTHERAPY IN THE TREATMENT OF MALIGNANT TUMORS.
Topics: Chlorambucil; Dactinomycin; Fluorouracil; Mitomycin; Mitomycins; Neoplasms; Toxicology | 1963 |
SIDE-EFFECTS OF COMBINED RADIATION AND CHEMOTHERAPY IN THE TREATMENT OF MALIGNANT TUMORS.
Topics: Chlorambucil; Dactinomycin; Fluorouracil; Mitomycin; Mitomycins; Neoplasms; Toxicology | 1963 |
DRUGS OF CURRENT USE FOR THE TREATMENT OF CANCER AND ALLIED DISEASES.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Antineoplastic Agents; Aziridines; Busulfan; Colchic | 1963 |
DRUGS OF CURRENT USE FOR THE TREATMENT OF CANCER AND ALLIED DISEASES.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Antineoplastic Agents; Aziridines; Busulfan; Colchic | 1963 |
THERAPEUTIC EFFECT OF ANTICANCER DRUGS ON SKIN CANCER.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Azaguanine; Carcinoma, Basal Cell; Carcinoma, Squamous | 1963 |
THERAPEUTIC EFFECT OF ANTICANCER DRUGS ON SKIN CANCER.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Azaguanine; Carcinoma, Basal Cell; Carcinoma, Squamous | 1963 |
[DRUG THERAPY OF UTERINE CANCER].
Topics: Antineoplastic Agents; Azaguanine; Blood Chemical Analysis; Catalase; Clinical Enzyme Tests; Deoxyri | 1964 |
[DRUG THERAPY OF UTERINE CANCER].
Topics: Antineoplastic Agents; Azaguanine; Blood Chemical Analysis; Catalase; Clinical Enzyme Tests; Deoxyri | 1964 |
ONCOLYSIS BY CLOSTRIDIA. III. EFFECTS OF CLOSTRIDIA AND CHEMOTHERAPEUTIC AGENTS ON RODENT TUMORS.
Topics: Adenocarcinoma; Animals; Antimetabolites; Antineoplastic Agents; Aziridines; Bacteriological Techniq | 1964 |
ONCOLYSIS BY CLOSTRIDIA. III. EFFECTS OF CLOSTRIDIA AND CHEMOTHERAPEUTIC AGENTS ON RODENT TUMORS.
Topics: Adenocarcinoma; Animals; Antimetabolites; Antineoplastic Agents; Aziridines; Bacteriological Techniq | 1964 |
CURRENT MANAGEMENT OF NEPHROBLASTOMA AND NEUROBLASTOMA.
Topics: Antineoplastic Agents; Child; Dactinomycin; Fluorouracil; Infant; Infant, Newborn; Kidney Neoplasms; | 1964 |
CURRENT MANAGEMENT OF NEPHROBLASTOMA AND NEUROBLASTOMA.
Topics: Antineoplastic Agents; Child; Dactinomycin; Fluorouracil; Infant; Infant, Newborn; Kidney Neoplasms; | 1964 |
PRESENT-DAY MANAGEMENT OF GASTRIC CANCER.
Topics: Fluorouracil; Gastrectomy; Humans; Mitomycin; Mitomycins; Mortality; Neoplasms; Stomach Neoplasms | 1964 |
PRESENT-DAY MANAGEMENT OF GASTRIC CANCER.
Topics: Fluorouracil; Gastrectomy; Humans; Mitomycin; Mitomycins; Mortality; Neoplasms; Stomach Neoplasms | 1964 |
[HISTOPATHOLOGICAL EFFECTS OF ANTINEOPLASTIC AGENTS ON MALIGNANT LYMPHOMA].
Topics: Antineoplastic Agents; Child; Chlorambucil; Cyclophosphamide; Dactinomycin; Geriatrics; Hodgkin Dise | 1964 |
[HISTOPATHOLOGICAL EFFECTS OF ANTINEOPLASTIC AGENTS ON MALIGNANT LYMPHOMA].
Topics: Antineoplastic Agents; Child; Chlorambucil; Cyclophosphamide; Dactinomycin; Geriatrics; Hodgkin Dise | 1964 |
STUDIES ON REGIONAL PERFUSION AND INTRA-ARTERIAL INFUSION FOR CANCER CHEMOTHERAPY.
Topics: Antineoplastic Agents; Breast Neoplasms; Celiac Artery; Chemotherapy, Cancer, Regional Perfusion; Co | 1964 |
STUDIES ON REGIONAL PERFUSION AND INTRA-ARTERIAL INFUSION FOR CANCER CHEMOTHERAPY.
Topics: Antineoplastic Agents; Breast Neoplasms; Celiac Artery; Chemotherapy, Cancer, Regional Perfusion; Co | 1964 |
[PREVENTION OF THE RECURRENCE OF CANCER].
Topics: Animals; Biomedical Research; Genetic Diseases, X-Linked; Hormones; Leukemia, Hairy Cell; Lymphatic | 1964 |
[PREVENTION OF THE RECURRENCE OF CANCER].
Topics: Animals; Biomedical Research; Genetic Diseases, X-Linked; Hormones; Leukemia, Hairy Cell; Lymphatic | 1964 |
[SUPPLEMENTARY THERAPEUTIC MEASURES TO PREVENT THE RECURRENCE OF BREAST CANCER USED IN ASSOCIATION WITH RADICAL SURGERY].
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Humans; Mastectomy; Mechlorethamine; Mito | 1964 |
[SUPPLEMENTARY THERAPEUTIC MEASURES TO PREVENT THE RECURRENCE OF BREAST CANCER USED IN ASSOCIATION WITH RADICAL SURGERY].
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Humans; Mastectomy; Mechlorethamine; Mito | 1964 |
[TOPICAL ADMINISTRATION OF CARCINOSTATIC AGENTS, WITH SPECIAL REFERENCE TO CONTINUOUS INTRA-ARTERIAL INJECTION AND TUMOR PERFUSION].
Topics: Administration, Topical; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cyclophosp | 1964 |
[TOPICAL ADMINISTRATION OF CARCINOSTATIC AGENTS, WITH SPECIAL REFERENCE TO CONTINUOUS INTRA-ARTERIAL INJECTION AND TUMOR PERFUSION].
Topics: Administration, Topical; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cyclophosp | 1964 |
[REGIONAL PERFUSION OF ANTINEOPLASTIC AGENTS FOR MALIGNANT TUMORS].
Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Injections, Intra-Arterial; Mechlor | 1964 |
[REGIONAL PERFUSION OF ANTINEOPLASTIC AGENTS FOR MALIGNANT TUMORS].
Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Injections, Intra-Arterial; Mechlor | 1964 |
[CHEMOTHERAPY OF PRIMARY AND METASTATIC HEPATIC CANCER BY HEPATIC ARTERY INFUSION].
Topics: Blood; Hepatic Artery; Humans; Injections, Intra-Arterial; Liver Function Tests; Liver Neoplasms; Mi | 1964 |
[CHEMOTHERAPY OF PRIMARY AND METASTATIC HEPATIC CANCER BY HEPATIC ARTERY INFUSION].
Topics: Blood; Hepatic Artery; Humans; Injections, Intra-Arterial; Liver Function Tests; Liver Neoplasms; Mi | 1964 |
[MASSIVE DOSES OF MITOMYCIN DURING SURGERY--THEORY AND RESULTS DURING PALLIATIVE EXCISION IN STOMACH CANCER].
Topics: Antineoplastic Agents; Biometry; Blood; Bone Marrow Transplantation; Gastrectomy; Geriatrics; Humans | 1964 |
[MASSIVE DOSES OF MITOMYCIN DURING SURGERY--THEORY AND RESULTS DURING PALLIATIVE EXCISION IN STOMACH CANCER].
Topics: Antineoplastic Agents; Biometry; Blood; Bone Marrow Transplantation; Gastrectomy; Geriatrics; Humans | 1964 |
[METASTATIC LUNG TUMOR: CHARACTERISTICS OF THE X-RAY PICTURE AND THE TREATMENT OF CHOICE IN PRIMARY TUMORS].
Topics: Antineoplastic Agents; Humans; Lung Neoplasms; Mitomycin; Neoplasm Metastasis; Neoplasms; Pneumonect | 1964 |
[METASTATIC LUNG TUMOR: CHARACTERISTICS OF THE X-RAY PICTURE AND THE TREATMENT OF CHOICE IN PRIMARY TUMORS].
Topics: Antineoplastic Agents; Humans; Lung Neoplasms; Mitomycin; Neoplasm Metastasis; Neoplasms; Pneumonect | 1964 |
CHEMOTHERAPY STUDIES ON PRIMARY TUMOR GRAFTS AND METASTASES IN HAMSTERS AND MICE.
Topics: Antineoplastic Agents; Cricetinae; Cyclophosphamide; Dactinomycin; Melphalan; Mice; Mitomycin; Mitom | 1964 |
CHEMOTHERAPY STUDIES ON PRIMARY TUMOR GRAFTS AND METASTASES IN HAMSTERS AND MICE.
Topics: Antineoplastic Agents; Cricetinae; Cyclophosphamide; Dactinomycin; Melphalan; Mice; Mitomycin; Mitom | 1964 |
THE ADVERSE EFFECTS OF CANCER CHEMOTHERAPY.
Topics: Animals; Antineoplastic Agents; Azaguanine; Carcinoma, Ehrlich Tumor; Cortisone; Cyclophosphamide; D | 1964 |
THE ADVERSE EFFECTS OF CANCER CHEMOTHERAPY.
Topics: Animals; Antineoplastic Agents; Azaguanine; Carcinoma, Ehrlich Tumor; Cortisone; Cyclophosphamide; D | 1964 |
HOST DEFENCE AND CHEMOTHERAPY IN EXPERIMENTAL CANCER.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Dactinomycin; Flavonoids; Lymphoma; Lymphoma, | 1964 |
HOST DEFENCE AND CHEMOTHERAPY IN EXPERIMENTAL CANCER.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Dactinomycin; Flavonoids; Lymphoma; Lymphoma, | 1964 |
CHEMOTHERAPY OF LEUKEMIA AND ALLIED DISEASES, WITH SPECIAL REFERENCE TO MYTOMYCIN C.
Topics: Blood; Bone Marrow; Hodgkin Disease; Humans; Leukemia; Leukemia, Myeloid; Mitomycin; Neoplasms | 1964 |
CHEMOTHERAPY OF LEUKEMIA AND ALLIED DISEASES, WITH SPECIAL REFERENCE TO MYTOMYCIN C.
Topics: Blood; Bone Marrow; Hodgkin Disease; Humans; Leukemia; Leukemia, Myeloid; Mitomycin; Neoplasms | 1964 |
ADMINISTRATION METHOD OF MITOMYCIN C.
Topics: Carcinoma, Hepatocellular; Liver Neoplasms; Methylcholanthrene; Mitomycin; Mitomycins; Neoplasms; Ne | 1964 |
ADMINISTRATION METHOD OF MITOMYCIN C.
Topics: Carcinoma, Hepatocellular; Liver Neoplasms; Methylcholanthrene; Mitomycin; Mitomycins; Neoplasms; Ne | 1964 |
THE CLINICAL EFFECTS OF THE CONTINUOUS INTRAVENOUS INFUSION OF CANCER CHEMOTHERAPEUTIC COMPOUNDS.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antineoplastic Agents; Floxuridine; Fluorouracil | 1964 |
THE CLINICAL EFFECTS OF THE CONTINUOUS INTRAVENOUS INFUSION OF CANCER CHEMOTHERAPEUTIC COMPOUNDS.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antineoplastic Agents; Floxuridine; Fluorouracil | 1964 |
ANALYSIS OF AGENTS FOR USE IN ISOLATED PERFUSION.
Topics: Chemotherapy, Cancer, Regional Perfusion; Dogs; Extremities; Fluorouracil; Mechlorethamine; Mitomyci | 1964 |
ANALYSIS OF AGENTS FOR USE IN ISOLATED PERFUSION.
Topics: Chemotherapy, Cancer, Regional Perfusion; Dogs; Extremities; Fluorouracil; Mechlorethamine; Mitomyci | 1964 |
PAPER ELECTROPHORETIC STUDIES ON SERUM PROTEINS IN THE DISEASES OF THE DIGESTIVE SYSTEM, WITH PARTICULAR REFERENCE TO THE CHANGES IN SERUM PROTEINS IN THE PATIENTS WITH CANCER.
Topics: Antineoplastic Agents; Blood Protein Electrophoresis; Blood Proteins; Carcinoma, Hepatocellular; Dig | 1963 |
PAPER ELECTROPHORETIC STUDIES ON SERUM PROTEINS IN THE DISEASES OF THE DIGESTIVE SYSTEM, WITH PARTICULAR REFERENCE TO THE CHANGES IN SERUM PROTEINS IN THE PATIENTS WITH CANCER.
Topics: Antineoplastic Agents; Blood Protein Electrophoresis; Blood Proteins; Carcinoma, Hepatocellular; Dig | 1963 |
CANCER CHEMOTHERAPY (MITOMYCIN-C) FOLLOWED BY BONE MARROW TRANSPLANTATION.
Topics: Bone Marrow Transplantation; Breast Neoplasms; Carcinoid Tumor; Carcinoma, Bronchogenic; Choriocarci | 1964 |
CANCER CHEMOTHERAPY (MITOMYCIN-C) FOLLOWED BY BONE MARROW TRANSPLANTATION.
Topics: Bone Marrow Transplantation; Breast Neoplasms; Carcinoid Tumor; Carcinoma, Bronchogenic; Choriocarci | 1964 |
[RENAL SARCOMA IN BOURNEVILLE-PRINGLE'S PHACOMATOSIS: CASE REPORT].
Topics: Humans; Kidney Neoplasms; Mitomycin; Mitomycins; Neoplasms; Nephrectomy; Neurocutaneous Syndromes; P | 1964 |
[RENAL SARCOMA IN BOURNEVILLE-PRINGLE'S PHACOMATOSIS: CASE REPORT].
Topics: Humans; Kidney Neoplasms; Mitomycin; Mitomycins; Neoplasms; Nephrectomy; Neurocutaneous Syndromes; P | 1964 |
[EXPERIMENTAL STUDIES ON THE PREVENTION OF HEMATOGENIC METASTASIS OF CANCER WITH ANTICANCER DRUGS].
Topics: Ascites; Blood Circulation; Injections, Intravenous; Liver Neoplasms; Mitomycin; Mitomycins; Neoplas | 1964 |
[EXPERIMENTAL STUDIES ON THE PREVENTION OF HEMATOGENIC METASTASIS OF CANCER WITH ANTICANCER DRUGS].
Topics: Ascites; Blood Circulation; Injections, Intravenous; Liver Neoplasms; Mitomycin; Mitomycins; Neoplas | 1964 |
TREATMENT OF MALIGNANT TUMOURS WITH 5-FLUOROURACIL IN 80 PATIENTS.
Topics: Biomedical Research; Breast Neoplasms; Colonic Neoplasms; Drug Therapy; Esophageal Neoplasms; Female | 1964 |
TREATMENT OF MALIGNANT TUMOURS WITH 5-FLUOROURACIL IN 80 PATIENTS.
Topics: Biomedical Research; Breast Neoplasms; Colonic Neoplasms; Drug Therapy; Esophageal Neoplasms; Female | 1964 |
VIROGENIC HAMSTER TUMOR CELLS: INDUCTION OF VIRUS SYNTHESIS.
Topics: Acridines; Adenoviridae; Adenoviridae Infections; Complement Fixation Tests; Cricetinae; Ependymoma; | 1964 |
VIROGENIC HAMSTER TUMOR CELLS: INDUCTION OF VIRUS SYNTHESIS.
Topics: Acridines; Adenoviridae; Adenoviridae Infections; Complement Fixation Tests; Cricetinae; Ependymoma; | 1964 |
[PRESENT POSSIBILITIES OF CHEMOPROPHYLAXIS, COMPLEMENTARY AND PALLIATIVE CHEMOTHERAPY IN ASSOCIATION WITH SURGERY IN THE TREATMENT OF UTERINE NEOPLASMS].
Topics: Adenocarcinoma; Antineoplastic Agents; Aziridines; Chemoprevention; Female; Fluorouracil; Humans; Mi | 1964 |
[PRESENT POSSIBILITIES OF CHEMOPROPHYLAXIS, COMPLEMENTARY AND PALLIATIVE CHEMOTHERAPY IN ASSOCIATION WITH SURGERY IN THE TREATMENT OF UTERINE NEOPLASMS].
Topics: Adenocarcinoma; Antineoplastic Agents; Aziridines; Chemoprevention; Female; Fluorouracil; Humans; Mi | 1964 |
INHIBITORY EFFECT OF ANTI-CANCER CHEMOTHERAPEUTICS ON LIVER METASTASIS OF INTRAPORTALLY INOCULATED MOUSE ASCITES HEPATOMA.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Ascites; Carcinoma, Hepatocellular; Injection | 1964 |
INHIBITORY EFFECT OF ANTI-CANCER CHEMOTHERAPEUTICS ON LIVER METASTASIS OF INTRAPORTALLY INOCULATED MOUSE ASCITES HEPATOMA.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Ascites; Carcinoma, Hepatocellular; Injection | 1964 |
THE COMBINED ACTION OF ANTI-TUMOR CHEMICALS AND 60CO GAMMA-RAY ON THE MOUSE STRAIN L CELLS CULTURED IN VITRO. I. EFFECT OF MITOMYCIN C.
Topics: Animals; Antineoplastic Agents; Cobalt Isotopes; DNA; DNA, Neoplasm; In Vitro Techniques; Mice; Mito | 1964 |
THE COMBINED ACTION OF ANTI-TUMOR CHEMICALS AND 60CO GAMMA-RAY ON THE MOUSE STRAIN L CELLS CULTURED IN VITRO. I. EFFECT OF MITOMYCIN C.
Topics: Animals; Antineoplastic Agents; Cobalt Isotopes; DNA; DNA, Neoplasm; In Vitro Techniques; Mice; Mito | 1964 |
PRESENT STATUS OF LEUKEMIA IN JAPAN WITH SPECIAL REFERENCE TO EPIDEMIOLOGY AND STUDIES ON THE EFFECT OF CHEMOTHERAPY.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Asian People; Busulfan; DNA; DNA, Neoplasm; Epidemio | 1964 |
PRESENT STATUS OF LEUKEMIA IN JAPAN WITH SPECIAL REFERENCE TO EPIDEMIOLOGY AND STUDIES ON THE EFFECT OF CHEMOTHERAPY.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Asian People; Busulfan; DNA; DNA, Neoplasm; Epidemio | 1964 |
[STUDIES ON THE EFFECTS OF MITOMYCIN C AGAINST PATIENTS WITH MALIGNANT TUMORS, PARTICULARLY ON THE CHANGES OF COAGULATING FACTORS].
Topics: Animals; Blood Coagulation Factors; Blood Coagulation Tests; Blood Platelets; Bone Marrow Examinatio | 1964 |
[STUDIES ON THE EFFECTS OF MITOMYCIN C AGAINST PATIENTS WITH MALIGNANT TUMORS, PARTICULARLY ON THE CHANGES OF COAGULATING FACTORS].
Topics: Animals; Blood Coagulation Factors; Blood Coagulation Tests; Blood Platelets; Bone Marrow Examinatio | 1964 |
RHABDOMYOSARCOMA OF THE HEAD AND NECK IN CHILDREN.
Topics: Adolescent; Child; Cyclophosphamide; Dactinomycin; Facial Neoplasms; Facial Paralysis; Head; Head an | 1964 |
RHABDOMYOSARCOMA OF THE HEAD AND NECK IN CHILDREN.
Topics: Adolescent; Child; Cyclophosphamide; Dactinomycin; Facial Neoplasms; Facial Paralysis; Head; Head an | 1964 |
[STUDIES ON THE EFFECTS OF MITOMYCIN C AGAINST PATIENTS WITH MALIGNANT TUMORS, PARTICULARLY ON THE CHANGES OF SERUM IRON, SERUM COPPER AND IRON BINDING CAPACITY. I. EFFECTS OF MITOMYCIN C AGAINST NORMAL DOGS].
Topics: Agranulocytosis; Anemia; Animals; Blood Chemical Analysis; Blood Platelets; Blood Protein Electropho | 1964 |
[STUDIES ON THE EFFECTS OF MITOMYCIN C AGAINST PATIENTS WITH MALIGNANT TUMORS, PARTICULARLY ON THE CHANGES OF SERUM IRON, SERUM COPPER AND IRON BINDING CAPACITY. I. EFFECTS OF MITOMYCIN C AGAINST NORMAL DOGS].
Topics: Agranulocytosis; Anemia; Animals; Blood Chemical Analysis; Blood Platelets; Blood Protein Electropho | 1964 |
A TECHNIQUE FOR PROLONGED CONTINUOUS INTRA-ARTERIAL INFUSION IN RABBITS. METHOD FOR THE COMPARISON OF THE EFFECTS OF ANTICANCER DRUGS BY CONTINUOUS INTRA-ARTERIAL INFUSION IN THE RABBIT BEARING VX2 CARCINOMAS IN EACH HIND LIMB.
Topics: Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Femoral Artery; Gangrene; Infusions, Int | 1964 |
A TECHNIQUE FOR PROLONGED CONTINUOUS INTRA-ARTERIAL INFUSION IN RABBITS. METHOD FOR THE COMPARISON OF THE EFFECTS OF ANTICANCER DRUGS BY CONTINUOUS INTRA-ARTERIAL INFUSION IN THE RABBIT BEARING VX2 CARCINOMAS IN EACH HIND LIMB.
Topics: Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Femoral Artery; Gangrene; Infusions, Int | 1964 |
ANTICANCER EFFECT OF POLYSACCHARIDE FRACTION PREPARED FROM BAMBOO GRASS.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Japan; Leukemia; Leukemia Virus, Murine; L | 1964 |
ANTICANCER EFFECT OF POLYSACCHARIDE FRACTION PREPARED FROM BAMBOO GRASS.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Japan; Leukemia; Leukemia Virus, Murine; L | 1964 |
CYTOCIDAL EFFECTS OF MITOMYCIN-C ON MH-134 ASCITES TUMOR CELLS IN VITRO.
Topics: Animals; Ascites; Carcinoma, Ehrlich Tumor; In Vitro Techniques; Mice; Mitomycin; Mitomycins; Neopla | 1964 |
CYTOCIDAL EFFECTS OF MITOMYCIN-C ON MH-134 ASCITES TUMOR CELLS IN VITRO.
Topics: Animals; Ascites; Carcinoma, Ehrlich Tumor; In Vitro Techniques; Mice; Mitomycin; Mitomycins; Neopla | 1964 |
THE USE OF RAT ASCITES TUMORS HETEROGRAFTED IN MICE FOR SCREENING OF ANTICANCEROUS AGENTS.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Ascites; Carcinoma, Ehrlich Tumor; Carcinoma, | 1963 |
THE USE OF RAT ASCITES TUMORS HETEROGRAFTED IN MICE FOR SCREENING OF ANTICANCEROUS AGENTS.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Ascites; Carcinoma, Ehrlich Tumor; Carcinoma, | 1963 |
[EXPERIMENTAL STUDIES ON THE EFFECT OF ANTI-CANCER CHEMOTHERAPEUTICS TO LIVER METASTASIS FOLLOWING PORTAL INJECTION OF MOUSE ASCITES HEPATOMA].
Topics: Animals; Ascites; Carcinoma, Hepatocellular; Liver Neoplasms; Lung Neoplasms; Mice; Mitomycin; Mitom | 1963 |
[EXPERIMENTAL STUDIES ON THE EFFECT OF ANTI-CANCER CHEMOTHERAPEUTICS TO LIVER METASTASIS FOLLOWING PORTAL INJECTION OF MOUSE ASCITES HEPATOMA].
Topics: Animals; Ascites; Carcinoma, Hepatocellular; Liver Neoplasms; Lung Neoplasms; Mice; Mitomycin; Mitom | 1963 |
AN EXPERIMENTAL STUDY OF SIMULTANEOUS IRRADIATION AND REGIONAL CHEMOTHERAPEUTIC PERFUSION.
Topics: Chemotherapy, Cancer, Regional Perfusion; Cyclophosphamide; Dactinomycin; Mitomycin; Mitomycins; Neo | 1964 |
AN EXPERIMENTAL STUDY OF SIMULTANEOUS IRRADIATION AND REGIONAL CHEMOTHERAPEUTIC PERFUSION.
Topics: Chemotherapy, Cancer, Regional Perfusion; Cyclophosphamide; Dactinomycin; Mitomycin; Mitomycins; Neo | 1964 |
SYNERGISM OF THE ANTINEOPLASTIC ACTIVITY OF CYTOSINE ARABINOSIDE BY PORFIROMYCIN.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Body Weight; Cytarabine; Cytosine; Leukemia; | 1964 |
SYNERGISM OF THE ANTINEOPLASTIC ACTIVITY OF CYTOSINE ARABINOSIDE BY PORFIROMYCIN.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Body Weight; Cytarabine; Cytosine; Leukemia; | 1964 |
STUDIES OF LEUKEMIA L1210 HOMOGRAFT IN SWISS HA-ICR MICE.
Topics: Allografts; Animals; Antineoplastic Agents; Leukemia L1210; Leukemia, Experimental; Mice; Mice, Inbr | 1964 |
STUDIES OF LEUKEMIA L1210 HOMOGRAFT IN SWISS HA-ICR MICE.
Topics: Allografts; Animals; Antineoplastic Agents; Leukemia L1210; Leukemia, Experimental; Mice; Mice, Inbr | 1964 |
OBSERVATIONS ON THE USE OF CANCER CHEMOTHERAPEUTIC AGENTS IN PATIENTS WITH MYCOSIS FUNGOIDES.
Topics: Alkylating Agents; Anti-Bacterial Agents; Antineoplastic Agents; Carbamates; Chlorambucil; Dactinomy | 1964 |
OBSERVATIONS ON THE USE OF CANCER CHEMOTHERAPEUTIC AGENTS IN PATIENTS WITH MYCOSIS FUNGOIDES.
Topics: Alkylating Agents; Anti-Bacterial Agents; Antineoplastic Agents; Carbamates; Chlorambucil; Dactinomy | 1964 |
[SOME PROBLEM OF SURGICAL OPERATION ACCOMPANIED WITH ANTICANCER AGENTS AND RADIATION THERAPY FOR MALIGNANT TUMORS, ESPECIALLY OF THEIR SIDE-EFFECTS].
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Cortisone; Dogs; Lung Diseases; Mitomycin; Mitom | 1964 |
[SOME PROBLEM OF SURGICAL OPERATION ACCOMPANIED WITH ANTICANCER AGENTS AND RADIATION THERAPY FOR MALIGNANT TUMORS, ESPECIALLY OF THEIR SIDE-EFFECTS].
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Cortisone; Dogs; Lung Diseases; Mitomycin; Mitom | 1964 |
[STUDIES ON CONTINUOUS INTRA-HYPOGASTRIC ARTERIAL INFUSION OF ANTICARCINOGENIC AGENTS IN PATIENTS WITH CERVICAL CANCER AS A SUPPLEMENTARY THERAPY TO SURGICAL OPERATION].
Topics: Anticarcinogenic Agents; Cyclophosphamide; Dogs; Drug Therapy; Female; Humans; Infusions, Intra-Arte | 1964 |
[STUDIES ON CONTINUOUS INTRA-HYPOGASTRIC ARTERIAL INFUSION OF ANTICARCINOGENIC AGENTS IN PATIENTS WITH CERVICAL CANCER AS A SUPPLEMENTARY THERAPY TO SURGICAL OPERATION].
Topics: Anticarcinogenic Agents; Cyclophosphamide; Dogs; Drug Therapy; Female; Humans; Infusions, Intra-Arte | 1964 |
THE CHEMOTHERAPY OF CANCER. (A PRELIMINARY REPORT OF ITS SCOPE IN WEST AFRICA).
Topics: Africa; Africa, Western; Alkylating Agents; Anti-Bacterial Agents; Antimetabolites; Antineoplastic A | 1964 |
THE CHEMOTHERAPY OF CANCER. (A PRELIMINARY REPORT OF ITS SCOPE IN WEST AFRICA).
Topics: Africa; Africa, Western; Alkylating Agents; Anti-Bacterial Agents; Antimetabolites; Antineoplastic A | 1964 |
IN VITRO CULTURE OF YOSHIDA SARCOMA CELLS: METHODS FOR DETERMINING ACQUIRED RESISTANCE TO DRUGS.
Topics: Animals; Antineoplastic Agents; Azaguanine; Culture Media; Cyclophosphamide; Dactinomycin; Drug Tole | 1964 |
IN VITRO CULTURE OF YOSHIDA SARCOMA CELLS: METHODS FOR DETERMINING ACQUIRED RESISTANCE TO DRUGS.
Topics: Animals; Antineoplastic Agents; Azaguanine; Culture Media; Cyclophosphamide; Dactinomycin; Drug Tole | 1964 |
[DEVELOPMENT OF FREE-CELL SUBLINES OF THE ASCITES HEPATOMA AH-130 AND THEIR BIOLOGICAL PROPERTIES].
Topics: Ascites; Carcinoma, Hepatocellular; Chromosomes; Electrons; Liver Neoplasms; Mechlorethamine; Micros | 1964 |
[DEVELOPMENT OF FREE-CELL SUBLINES OF THE ASCITES HEPATOMA AH-130 AND THEIR BIOLOGICAL PROPERTIES].
Topics: Ascites; Carcinoma, Hepatocellular; Chromosomes; Electrons; Liver Neoplasms; Mechlorethamine; Micros | 1964 |
[EXPERIMENTAL ANTICANCER STUDIES. 23. FURTHER EXPERIMENTS ON THE ANTITUMOR ACTIVITY OF 4-AMINO-6-OCTYLRESORCINOL HYDROCHLORIDE].
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Leukemia; Leuke | 1964 |
[EXPERIMENTAL ANTICANCER STUDIES. 23. FURTHER EXPERIMENTS ON THE ANTITUMOR ACTIVITY OF 4-AMINO-6-OCTYLRESORCINOL HYDROCHLORIDE].
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Leukemia; Leuke | 1964 |
[EFFECT OF MITOMYCIN-C INJECTION ON LYSOSOMAL ENZYMIC ACTIVITIES OF YOSHIDA ASCITES SARCOMA].
Topics: Acid Phosphatase; Animals; Ascites; Deoxyribonucleases; DNA; Histocytochemistry; Lysosomes; Mitomyci | 1964 |
[EFFECT OF MITOMYCIN-C INJECTION ON LYSOSOMAL ENZYMIC ACTIVITIES OF YOSHIDA ASCITES SARCOMA].
Topics: Acid Phosphatase; Animals; Ascites; Deoxyribonucleases; DNA; Histocytochemistry; Lysosomes; Mitomyci | 1964 |
[EVALUATION OF ADJUVANT POSTOPERATIVE CHEMOTHERAPY AND RADIATION THERAPY IN GASTRIC CANCER].
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Therapy; Humans; Mitomycin; Mitomycins; Neoplasm | 1964 |
[EVALUATION OF ADJUVANT POSTOPERATIVE CHEMOTHERAPY AND RADIATION THERAPY IN GASTRIC CANCER].
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Therapy; Humans; Mitomycin; Mitomycins; Neoplasm | 1964 |
EFFECT OF DRUGS ON CELL AND VIRUS GROWTH IN FRIEND LEUKEMIA AND A TUMOR VARIANT.
Topics: Animals; Estradiol; Friends; Leukemia; Leukemia Virus, Murine; Leukemia, Experimental; Lymphoma, Lar | 1965 |
EFFECT OF DRUGS ON CELL AND VIRUS GROWTH IN FRIEND LEUKEMIA AND A TUMOR VARIANT.
Topics: Animals; Estradiol; Friends; Leukemia; Leukemia Virus, Murine; Leukemia, Experimental; Lymphoma, Lar | 1965 |
[INTRAOPERATIVE USE OF MITOMYCIN C WITH SPLEEN AND BONE MARROW SHIELDING TECHNIQUE IN GASTRIC CANCER SURGERY].
Topics: Bone Marrow; Drug Therapy; Humans; Mitomycin; Mitomycins; Neoplasms; Spleen; Stomach Neoplasms; Surg | 1965 |
[INTRAOPERATIVE USE OF MITOMYCIN C WITH SPLEEN AND BONE MARROW SHIELDING TECHNIQUE IN GASTRIC CANCER SURGERY].
Topics: Bone Marrow; Drug Therapy; Humans; Mitomycin; Mitomycins; Neoplasms; Spleen; Stomach Neoplasms; Surg | 1965 |
DIFFERENTIAL EFFECTS OF INHIBITORS ON THE STEPS LEADING TO THE FORMATION OF SV40 TUMOR AND VIRUS ANTIGENS.
Topics: Animals; Antigens; Antigens, Viral; Antimetabolites; Chlorocebus aethiops; Complement Fixation Tests | 1965 |
DIFFERENTIAL EFFECTS OF INHIBITORS ON THE STEPS LEADING TO THE FORMATION OF SV40 TUMOR AND VIRUS ANTIGENS.
Topics: Animals; Antigens; Antigens, Viral; Antimetabolites; Chlorocebus aethiops; Complement Fixation Tests | 1965 |
EFFECT OF PHLEOMYCIN ON DNA POLYMERASE OF TUMOR ORIGIN.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Carcinoma 256, Walker; DNA-Directed DNA Polymerase; Mi | 1965 |
EFFECT OF PHLEOMYCIN ON DNA POLYMERASE OF TUMOR ORIGIN.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Carcinoma 256, Walker; DNA-Directed DNA Polymerase; Mi | 1965 |
CHEMOTHERAPY OF BREAST CANCER.
Topics: Antineoplastic Agents; Biomedical Research; Breast Neoplasms; Carcinoma, Ductal; Cyclophosphamide; F | 1965 |
CHEMOTHERAPY OF BREAST CANCER.
Topics: Antineoplastic Agents; Biomedical Research; Breast Neoplasms; Carcinoma, Ductal; Cyclophosphamide; F | 1965 |
An evaluation of actinomycin D and mitomycin C in patients with advanced cancer.
Topics: Anti-Bacterial Agents; Dactinomycin; Mitomycin; Neoplasms | 1961 |
An evaluation of actinomycin D and mitomycin C in patients with advanced cancer.
Topics: Anti-Bacterial Agents; Dactinomycin; Mitomycin; Neoplasms | 1961 |
Action of mitomycin C on nucleic acid metabolism in tumor and bacterial cells.
Topics: Anti-Bacterial Agents; Biochemical Phenomena; Dermatologic Agents; DNA; Escherichia coli; Mitomycin; | 1962 |
Action of mitomycin C on nucleic acid metabolism in tumor and bacterial cells.
Topics: Anti-Bacterial Agents; Biochemical Phenomena; Dermatologic Agents; DNA; Escherichia coli; Mitomycin; | 1962 |
The influences of mitomycin C and carzinophilin upon methylcholanthrene sarcoma in rats. (A preliminary report).
Topics: Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Antineoplastic Agents; Methylcholan | 1961 |
The influences of mitomycin C and carzinophilin upon methylcholanthrene sarcoma in rats. (A preliminary report).
Topics: Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Antineoplastic Agents; Methylcholan | 1961 |
Role of GRP58 in mitomycin C-induced DNA cross-linking.
Topics: Amino Acid Sequence; Animals; Antibiotics, Antineoplastic; CHO Cells; Cricetinae; Cross-Linking Reag | 2003 |
Role of GRP58 in mitomycin C-induced DNA cross-linking.
Topics: Amino Acid Sequence; Animals; Antibiotics, Antineoplastic; CHO Cells; Cricetinae; Cross-Linking Reag | 2003 |
Comet assay and flow cytometry analysis of DNA repair in normal and cancer cells treated with known mutagens with different mechanisms of action.
Topics: Cell Cycle; Cells, Cultured; Comet Assay; Cross-Linking Reagents; DNA; DNA Damage; DNA Repair; DNA, | 2003 |
Comet assay and flow cytometry analysis of DNA repair in normal and cancer cells treated with known mutagens with different mechanisms of action.
Topics: Cell Cycle; Cells, Cultured; Comet Assay; Cross-Linking Reagents; DNA; DNA Damage; DNA Repair; DNA, | 2003 |
Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin.
Topics: Animals; Annexin A5; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Body Weigh | 2004 |
Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin.
Topics: Animals; Annexin A5; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Body Weigh | 2004 |
Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME).
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Membrane Permeability; Drug Delivery Systems; | 2004 |
Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME).
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Membrane Permeability; Drug Delivery Systems; | 2004 |
Involvement of mammalian Mus81 in genome integrity and tumor suppression.
Topics: Alleles; Animals; Chromosome Aberrations; DNA Damage; DNA-Binding Proteins; Embryo, Mammalian; Embry | 2004 |
Involvement of mammalian Mus81 in genome integrity and tumor suppression.
Topics: Alleles; Animals; Chromosome Aberrations; DNA Damage; DNA-Binding Proteins; Embryo, Mammalian; Embry | 2004 |
The DNA double-stranded break repair protein endo-exonuclease as a therapeutic target for cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; | 2004 |
The DNA double-stranded break repair protein endo-exonuclease as a therapeutic target for cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; | 2004 |
Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.
Topics: Animals; BRCA2 Protein; Centrosome; Chromosome Segregation; Cross-Linking Reagents; DNA, Complementa | 2005 |
Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.
Topics: Animals; BRCA2 Protein; Centrosome; Chromosome Segregation; Cross-Linking Reagents; DNA, Complementa | 2005 |
Effect of NQO1 induction on the antitumor activity of RH1 in human tumors in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Aziridines; Benzoquinones; Cell Line, Tumor; Cell Survival; Dose-Res | 2005 |
Effect of NQO1 induction on the antitumor activity of RH1 in human tumors in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Aziridines; Benzoquinones; Cell Line, Tumor; Cell Survival; Dose-Res | 2005 |
Preparation and characterization of Mitomycin-C loaded chitosan-coated alginate microspheres for chemoembolization.
Topics: Alginates; Antibiotics, Antineoplastic; Biocompatible Materials; Calcium Chloride; Chemoembolization | 2005 |
Preparation and characterization of Mitomycin-C loaded chitosan-coated alginate microspheres for chemoembolization.
Topics: Alginates; Antibiotics, Antineoplastic; Biocompatible Materials; Calcium Chloride; Chemoembolization | 2005 |
Solid tumor chemotherapy with mitomycin C.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Female; Humans; Male; Middle Aged; Mitomycin; | 1967 |
Solid tumor chemotherapy with mitomycin C.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Female; Humans; Male; Middle Aged; Mitomycin; | 1967 |
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antibiotics, Antineoplastic; Apoptosis; Caspase Inhibitors | 2005 |
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antibiotics, Antineoplastic; Apoptosis; Caspase Inhibitors | 2005 |
New enzyme for reductive cancer chemotherapy, YieF, and its improvement by directed evolution.
Topics: Antineoplastic Agents; Aziridines; Drug Delivery Systems; Escherichia coli Proteins; Evolution, Mole | 2006 |
New enzyme for reductive cancer chemotherapy, YieF, and its improvement by directed evolution.
Topics: Antineoplastic Agents; Aziridines; Drug Delivery Systems; Escherichia coli Proteins; Evolution, Mole | 2006 |
Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; Doxorubicin; Female; Human | 2006 |
Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; Doxorubicin; Female; Human | 2006 |
Stochastic cancer progression driven by non-clonal chromosome aberrations.
Topics: Animals; Cell Line; Cell Line, Transformed; Cell Line, Tumor; Cell Transformation, Viral; Cells, Cul | 2006 |
Stochastic cancer progression driven by non-clonal chromosome aberrations.
Topics: Animals; Cell Line; Cell Line, Transformed; Cell Line, Tumor; Cell Transformation, Viral; Cells, Cul | 2006 |
p53 targets identified by protein expression profiling.
Topics: Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Electrophoresis, Gel, Two-Dimensional; Gene Expressi | 2007 |
p53 targets identified by protein expression profiling.
Topics: Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Electrophoresis, Gel, Two-Dimensional; Gene Expressi | 2007 |
The human endonuclease III enzyme is a relevant target to potentiate cisplatin cytotoxicity in Y-box-binding protein-1 overexpressing tumor cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Deoxyribonuclease (Pyrimidine Dimer); Drug Resis | 2008 |
The human endonuclease III enzyme is a relevant target to potentiate cisplatin cytotoxicity in Y-box-binding protein-1 overexpressing tumor cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Deoxyribonuclease (Pyrimidine Dimer); Drug Resis | 2008 |
Rapid lentiviral transduction preserves the engraftment potential of Fanca(-/-) hematopoietic stem cells.
Topics: Animals; Cell Lineage; Fanconi Anemia; Fanconi Anemia Complementation Group A Protein; Gene Transfer | 2008 |
Rapid lentiviral transduction preserves the engraftment potential of Fanca(-/-) hematopoietic stem cells.
Topics: Animals; Cell Lineage; Fanconi Anemia; Fanconi Anemia Complementation Group A Protein; Gene Transfer | 2008 |
Single-molecule PCR analysis of germ line mutation induction by anticancer drugs in mice.
Topics: Animals; Antineoplastic Agents; Bleomycin; Cyclophosphamide; DNA Mutational Analysis; Dose-Response | 2008 |
Single-molecule PCR analysis of germ line mutation induction by anticancer drugs in mice.
Topics: Animals; Antineoplastic Agents; Bleomycin; Cyclophosphamide; DNA Mutational Analysis; Dose-Response | 2008 |
[Arterial administration of SMANCS and other antitumor agents dissolved in lipiodol for various malignant solid tumors].
Topics: Aclarubicin; Animals; Antibiotics, Antineoplastic; Furans; Humans; Infusions, Intra-Arterial; Iodize | 1984 |
[Arterial administration of SMANCS and other antitumor agents dissolved in lipiodol for various malignant solid tumors].
Topics: Aclarubicin; Animals; Antibiotics, Antineoplastic; Furans; Humans; Infusions, Intra-Arterial; Iodize | 1984 |
[Chemosensitivity of adriamycin, mitomycin C, and bleomycin with in vitro colony assay].
Topics: Bleomycin; Cell Division; Cells, Cultured; Doxorubicin; Drug Evaluation, Preclinical; Drug Resistanc | 1982 |
[Chemosensitivity of adriamycin, mitomycin C, and bleomycin with in vitro colony assay].
Topics: Bleomycin; Cell Division; Cells, Cultured; Doxorubicin; Drug Evaluation, Preclinical; Drug Resistanc | 1982 |
[Selective arterial chemo-embolization with microencapsulated anticancer drugs].
Topics: Antibiotics, Antineoplastic; Bleomycin; Capsules; Female; Humans; Male; Mitomycin; Mitomycins; Neopl | 1983 |
[Selective arterial chemo-embolization with microencapsulated anticancer drugs].
Topics: Antibiotics, Antineoplastic; Bleomycin; Capsules; Female; Humans; Male; Mitomycin; Mitomycins; Neopl | 1983 |
[Experimental research to clinical application of interferons].
Topics: Animals; Bleomycin; Cytarabine; Drug Therapy, Combination; Humans; Interferon Inducers; Interferon T | 1984 |
[Experimental research to clinical application of interferons].
Topics: Animals; Bleomycin; Cytarabine; Drug Therapy, Combination; Humans; Interferon Inducers; Interferon T | 1984 |
Comparison of drug sensitivity among tumor cells within a tumor, between primary tumor and metastases, and between different metastases in the human tumor colony-forming assay.
Topics: Antineoplastic Agents; Bleomycin; Cell Division; Cell Survival; Cells, Cultured; Cisplatin; Doxorubi | 1984 |
Comparison of drug sensitivity among tumor cells within a tumor, between primary tumor and metastases, and between different metastases in the human tumor colony-forming assay.
Topics: Antineoplastic Agents; Bleomycin; Cell Division; Cell Survival; Cells, Cultured; Cisplatin; Doxorubi | 1984 |
[The clinical effect of hyperthermia combined with induced hypertension chemotherapy].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Pressure; Cisplatin | 1984 |
[The clinical effect of hyperthermia combined with induced hypertension chemotherapy].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Pressure; Cisplatin | 1984 |
Chemotactic activity for mononuclear phagocytes of culture supernatants from murine and human tumor cells: evidence for a role in the regulation of the macrophage content of neoplastic tissues.
Topics: Animals; Cell Line; Cells, Cultured; Chemotactic Factors; Chemotaxis; Cycloheximide; Female; Humans; | 1983 |
Chemotactic activity for mononuclear phagocytes of culture supernatants from murine and human tumor cells: evidence for a role in the regulation of the macrophage content of neoplastic tissues.
Topics: Animals; Cell Line; Cells, Cultured; Chemotactic Factors; Chemotaxis; Cycloheximide; Female; Humans; | 1983 |
Cancer chemotherapy via ambulatory infusion pump.
Topics: Ambulatory Care; Antineoplastic Agents; Doxorubicin; Fluorouracil; Humans; Infusions, Parenteral; Mi | 1983 |
Cancer chemotherapy via ambulatory infusion pump.
Topics: Ambulatory Care; Antineoplastic Agents; Doxorubicin; Fluorouracil; Humans; Infusions, Parenteral; Mi | 1983 |
[Cancer chemotherapy in combination with angiotensin-induced hypertension].
Topics: Angiotensin II; Animals; Blood Pressure; Carbazilquinone; Doxorubicin; Drug Therapy, Combination; Fl | 1983 |
[Cancer chemotherapy in combination with angiotensin-induced hypertension].
Topics: Angiotensin II; Animals; Blood Pressure; Carbazilquinone; Doxorubicin; Drug Therapy, Combination; Fl | 1983 |
The effects of total-body hyperthermia combined with anticancer drugs on immunity in advanced cancer patients.
Topics: Adult; Antineoplastic Agents; Complement System Proteins; Cyclophosphamide; Doxorubicin; Female; Fev | 1983 |
The effects of total-body hyperthermia combined with anticancer drugs on immunity in advanced cancer patients.
Topics: Adult; Antineoplastic Agents; Complement System Proteins; Cyclophosphamide; Doxorubicin; Female; Fev | 1983 |
Pharmacokinetics of mitomycin C in humans.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Ascitic Fluid; Bile; Chromatography, High Pressure Liquid; | 1983 |
Pharmacokinetics of mitomycin C in humans.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Ascitic Fluid; Bile; Chromatography, High Pressure Liquid; | 1983 |
Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Kinetics; Male; Met | 1983 |
Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Kinetics; Male; Met | 1983 |
[Our initial experience with mitomycin C in anticancer chemotherapy].
Topics: Antibiotics, Antineoplastic; Female; Humans; Male; Mitomycin; Mitomycins; Neoplasms | 1983 |
[Our initial experience with mitomycin C in anticancer chemotherapy].
Topics: Antibiotics, Antineoplastic; Female; Humans; Male; Mitomycin; Mitomycins; Neoplasms | 1983 |
Feasibility study of combining metronidazole with chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carcinoma, Sq | 1983 |
Feasibility study of combining metronidazole with chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carcinoma, Sq | 1983 |
Cytotoxicity of mitomycin C on clonogenic human carcinoma cells is not enhanced by hypoxia.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line; Colonic Neoplasms; Humans; Mice; Mitomycin; Mitomyc | 1984 |
Cytotoxicity of mitomycin C on clonogenic human carcinoma cells is not enhanced by hypoxia.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line; Colonic Neoplasms; Humans; Mice; Mitomycin; Mitomyc | 1984 |
Drug resistance of hypoxic tumour cells in vitro.
Topics: Animals; Anthracenes; Cell Line; DNA, Single-Stranded; Drug Evaluation, Preclinical; Drug Resistance | 1984 |
Drug resistance of hypoxic tumour cells in vitro.
Topics: Animals; Anthracenes; Cell Line; DNA, Single-Stranded; Drug Evaluation, Preclinical; Drug Resistance | 1984 |
[Pharmacokinetics of mitomycin C in cancer patients during prolonged administration of the preparation].
Topics: Breast Neoplasms; Female; Humans; Infusions, Parenteral; Kinetics; Mitomycin; Mitomycins; Neoplasms; | 1984 |
[Pharmacokinetics of mitomycin C in cancer patients during prolonged administration of the preparation].
Topics: Breast Neoplasms; Female; Humans; Infusions, Parenteral; Kinetics; Mitomycin; Mitomycins; Neoplasms; | 1984 |
Cytolytic activity of interferon-gamma and its synergism with 5-fluorouracil.
Topics: Antibodies, Monoclonal; Cell Line; Cytotoxicity, Immunologic; Dose-Response Relationship, Drug; Drug | 1984 |
Cytolytic activity of interferon-gamma and its synergism with 5-fluorouracil.
Topics: Antibodies, Monoclonal; Cell Line; Cytotoxicity, Immunologic; Dose-Response Relationship, Drug; Drug | 1984 |
[Phase I-II study of 7-N-(P-hydroxyphenyl)-mitomycin C (KW2083, M83)].
Topics: Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Colonic Neoplasms; Drug Evaluation; Female; Hum | 1984 |
[Phase I-II study of 7-N-(P-hydroxyphenyl)-mitomycin C (KW2083, M83)].
Topics: Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Colonic Neoplasms; Drug Evaluation; Female; Hum | 1984 |
[Phase II study of KW 2083 [7-N-(p-hydroxyphenyl)-mitomycin C] in patients with various cancers].
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Anorexia; Antibiotics, Antineoplastic; Aspartate Amin | 1984 |
[Phase II study of KW 2083 [7-N-(p-hydroxyphenyl)-mitomycin C] in patients with various cancers].
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Anorexia; Antibiotics, Antineoplastic; Aspartate Amin | 1984 |
Phase I clinical trial with a combination of methotrexate and mitomycin C.
Topics: Adult; Aged; Drug Evaluation; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Humans; Ma | 1981 |
Phase I clinical trial with a combination of methotrexate and mitomycin C.
Topics: Adult; Aged; Drug Evaluation; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Humans; Ma | 1981 |
Drug activity and therapeutic synergism in cancer treatment.
Topics: Animals; Antineoplastic Agents; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration S | 1982 |
Drug activity and therapeutic synergism in cancer treatment.
Topics: Animals; Antineoplastic Agents; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration S | 1982 |
Hypoxic cell specific chemotherapeutic agents.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Cells, Cultured; Chemical Phenomena; Chemistry, P | 1982 |
Hypoxic cell specific chemotherapeutic agents.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Cells, Cultured; Chemical Phenomena; Chemistry, P | 1982 |
[Clinical studies of cancer chemotherapy combined with angiotensin-II (ANG-II)].
Topics: Adult; Aged; Angiotensin II; Antibiotics, Antineoplastic; Antineoplastic Agents; Blood Pressure; Bre | 1982 |
[Clinical studies of cancer chemotherapy combined with angiotensin-II (ANG-II)].
Topics: Adult; Aged; Angiotensin II; Antibiotics, Antineoplastic; Antineoplastic Agents; Blood Pressure; Bre | 1982 |
[Phase I study of KW2083 7-N-(p-hydroxyphenyl) mitomycin C].
Topics: Animals; Anorexia; Drug Evaluation; Humans; Mice; Mitomycin; Mitomycins; Nausea; Neoplasms; Vomiting | 1982 |
[Phase I study of KW2083 7-N-(p-hydroxyphenyl) mitomycin C].
Topics: Animals; Anorexia; Drug Evaluation; Humans; Mice; Mitomycin; Mitomycins; Nausea; Neoplasms; Vomiting | 1982 |
Anticancer chemosensitivity changes between the original and recurrent tumors after successful chemotherapy selected according to the sensitivity assay.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; DNA, Neoplasm; Dox | 1995 |
Anticancer chemosensitivity changes between the original and recurrent tumors after successful chemotherapy selected according to the sensitivity assay.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; DNA, Neoplasm; Dox | 1995 |
[Clinical application of drug delivery system of anti-cancer drugs--the pharmacokinetics and clinical results].
Topics: Antibodies, Monoclonal; Drug Delivery Systems; Fluorouracil; Humans; Immunotoxins; Iodized Oil; Mito | 1993 |
[Clinical application of drug delivery system of anti-cancer drugs--the pharmacokinetics and clinical results].
Topics: Antibodies, Monoclonal; Drug Delivery Systems; Fluorouracil; Humans; Immunotoxins; Iodized Oil; Mito | 1993 |
[Biological basis of thermochemotherapy].
Topics: Antineoplastic Agents; Cell Hypoxia; Combined Modality Therapy; Humans; Hyperthermia, Induced; Mitom | 1993 |
[Biological basis of thermochemotherapy].
Topics: Antineoplastic Agents; Cell Hypoxia; Combined Modality Therapy; Humans; Hyperthermia, Induced; Mitom | 1993 |
Targeted cancer chemotherapy with arterial microcapsule chemoembolization: review of 1013 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Che | 1996 |
Targeted cancer chemotherapy with arterial microcapsule chemoembolization: review of 1013 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Che | 1996 |
Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9.
Topics: Antineoplastic Agents; Aziridines; Cytochrome Reductases; Cytochrome-B(5) Reductase; Humans; Indoleq | 1996 |
Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9.
Topics: Antineoplastic Agents; Aziridines; Cytochrome Reductases; Cytochrome-B(5) Reductase; Humans; Indoleq | 1996 |
Investigation of the comparative effects of 2-chlorodeoxyadenosine on tumor colony forming units in vitro.
Topics: Antineoplastic Agents; Cell Division; Cisplatin; Cladribine; Dose-Response Relationship, Drug; Doxor | 1995 |
Investigation of the comparative effects of 2-chlorodeoxyadenosine on tumor colony forming units in vitro.
Topics: Antineoplastic Agents; Cell Division; Cisplatin; Cladribine; Dose-Response Relationship, Drug; Doxor | 1995 |
Hypersensitivity to mitomycin C-induced sister chromatid exchange as a biomarker of past exposure to arsenic.
Topics: Aged; Arsenic; Biomarkers; Carcinogens; Environmental Exposure; Feasibility Studies; Female; Fresh W | 1996 |
Hypersensitivity to mitomycin C-induced sister chromatid exchange as a biomarker of past exposure to arsenic.
Topics: Aged; Arsenic; Biomarkers; Carcinogens; Environmental Exposure; Feasibility Studies; Female; Fresh W | 1996 |
Molecular targeting of mitomycin C chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; DNA Damage; Drug Resistance, Neoplasm; Drug Screening Assays, | 1997 |
Molecular targeting of mitomycin C chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; DNA Damage; Drug Resistance, Neoplasm; Drug Screening Assays, | 1997 |
Proliferation indices as molecular pharmacodynamic endpoints in evaluation of anticancer drug effect in human solid tumors.
Topics: Antineoplastic Agents; Bromodeoxyuridine; Cell Division; DNA; Doxorubicin; Humans; Mitomycin; Neopla | 1998 |
Proliferation indices as molecular pharmacodynamic endpoints in evaluation of anticancer drug effect in human solid tumors.
Topics: Antineoplastic Agents; Bromodeoxyuridine; Cell Division; DNA; Doxorubicin; Humans; Mitomycin; Neopla | 1998 |
Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small C | 1997 |
Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small C | 1997 |
Mitomycin C induced chromosomal aberrations in young cancer patients.
Topics: Adult; Age Factors; Aged; Antibiotics, Antineoplastic; Child; Child, Preschool; Chromatids; Chromoso | 1998 |
Mitomycin C induced chromosomal aberrations in young cancer patients.
Topics: Adult; Age Factors; Aged; Antibiotics, Antineoplastic; Child; Child, Preschool; Chromatids; Chromoso | 1998 |
Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: implications for enzyme-directed bioreductive drug development.
Topics: Animals; Antibiotics, Antineoplastic; Biotransformation; Drug Screening Assays, Antitumor; Humans; M | 2000 |
Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: implications for enzyme-directed bioreductive drug development.
Topics: Animals; Antibiotics, Antineoplastic; Biotransformation; Drug Screening Assays, Antitumor; Humans; M | 2000 |
Staurosporine and conventional anticancer drugs induce overlapping, yet distinct pathways of apoptosis and caspase activation.
Topics: Antineoplastic Agents; Apoptosis; Caspases; Enzyme Activation; Etoposide; fas Receptor; HeLa Cells; | 2001 |
Staurosporine and conventional anticancer drugs induce overlapping, yet distinct pathways of apoptosis and caspase activation.
Topics: Antineoplastic Agents; Apoptosis; Caspases; Enzyme Activation; Etoposide; fas Receptor; HeLa Cells; | 2001 |
The association between frequencies of mitomycin C-induced sister chromatid exchange and cancer risk in arseniasis.
Topics: Arsenic; Arsenic Poisoning; Biomarkers; Cells, Cultured; Drug Synergism; Female; Follow-Up Studies; | 2002 |
The association between frequencies of mitomycin C-induced sister chromatid exchange and cancer risk in arseniasis.
Topics: Arsenic; Arsenic Poisoning; Biomarkers; Cells, Cultured; Drug Synergism; Female; Follow-Up Studies; | 2002 |
Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C.
Topics: Aged; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eosinophilia; | 1992 |
Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C.
Topics: Aged; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eosinophilia; | 1992 |
Chemotherapy of solid tumors in private practice in Malaysia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Drug | 1992 |
Chemotherapy of solid tumors in private practice in Malaysia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Drug | 1992 |
[Evaluation of implantation of a cancer chemotherapeutic vascular access device: report of 91 cases].
Topics: Catheters, Indwelling; Cisplatin; Evaluation Studies as Topic; Femoral Artery; Fluorouracil; Humans; | 1992 |
[Evaluation of implantation of a cancer chemotherapeutic vascular access device: report of 91 cases].
Topics: Catheters, Indwelling; Cisplatin; Evaluation Studies as Topic; Femoral Artery; Fluorouracil; Humans; | 1992 |
[Nephrotic syndrome associated with neoplasms and malignant lymphoma].
Topics: Adult; Aged; Cyclophosphamide; Female; Fluorouracil; Humans; Lymphoma; Male; Middle Aged; Mitomycin; | 1992 |
[Nephrotic syndrome associated with neoplasms and malignant lymphoma].
Topics: Adult; Aged; Cyclophosphamide; Female; Fluorouracil; Humans; Lymphoma; Male; Middle Aged; Mitomycin; | 1992 |
Morphometric and colorimetric analyses of human tumor cell line growth and drug sensitivity in soft agar culture.
Topics: Bleomycin; Carmustine; Cell Division; Cell Line; Chlorambucil; Cisplatin; Colony-Forming Units Assay | 1991 |
Morphometric and colorimetric analyses of human tumor cell line growth and drug sensitivity in soft agar culture.
Topics: Bleomycin; Carmustine; Cell Division; Cell Line; Chlorambucil; Cisplatin; Colony-Forming Units Assay | 1991 |
[Nutritional support for cancer bearing patients].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Fluorouracil; Home Nursing; Humans | 1991 |
[Nutritional support for cancer bearing patients].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Fluorouracil; Home Nursing; Humans | 1991 |
Studies on the mechanism of resistance to mitomycin C and porfiromycin in a human cell strain derived from a cancer-prone individual.
Topics: Cell Line; Cell Survival; Child; Drug Resistance; Female; Glutathione; Humans; Kinetics; Mitomycin; | 1991 |
Studies on the mechanism of resistance to mitomycin C and porfiromycin in a human cell strain derived from a cancer-prone individual.
Topics: Cell Line; Cell Survival; Child; Drug Resistance; Female; Glutathione; Humans; Kinetics; Mitomycin; | 1991 |
DT-diaphorase activity and mitomycin C sensitivity in non-transformed cell strains derived from members of a cancer-prone family.
Topics: Adolescent; Adult; Aged; DNA; Drug Resistance; Female; Fibroblasts; Humans; Male; Middle Aged; Mitom | 1991 |
DT-diaphorase activity and mitomycin C sensitivity in non-transformed cell strains derived from members of a cancer-prone family.
Topics: Adolescent; Adult; Aged; DNA; Drug Resistance; Female; Fibroblasts; Humans; Male; Middle Aged; Mitom | 1991 |
[Arterial infusion chemotherapy combined with biochemical modulation in cancer patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouraci | 1991 |
[Arterial infusion chemotherapy combined with biochemical modulation in cancer patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouraci | 1991 |
Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1 alpha.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Screening Assays, Antit | 1991 |
Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1 alpha.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Screening Assays, Antit | 1991 |
Clinical usefulness of chemosensitivity testing using the MTT assay.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Doxorubici | 1991 |
Clinical usefulness of chemosensitivity testing using the MTT assay.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Doxorubici | 1991 |
Generation of lymphokine-activated killer cell activity by low-dose recombinant interleukin-2 and tumor cells.
Topics: Antigens, CD; Antigens, Differentiation, T-Lymphocyte; CD2 Antigens; Cells, Cultured; Cytotoxicity, | 1990 |
Generation of lymphokine-activated killer cell activity by low-dose recombinant interleukin-2 and tumor cells.
Topics: Antigens, CD; Antigens, Differentiation, T-Lymphocyte; CD2 Antigens; Cells, Cultured; Cytotoxicity, | 1990 |
Clinical evaluation of chemotherapy under angiotensin II-induced hypertension in patients with advanced cancer.
Topics: Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Cisplatin; Dox | 1990 |
Clinical evaluation of chemotherapy under angiotensin II-induced hypertension in patients with advanced cancer.
Topics: Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Cisplatin; Dox | 1990 |
[Topical application of mitomycin C conjugated with dextran (MMC-D): a high molecular weight derivative of mitomycin C].
Topics: Aged; Animals; Antibiotics, Antineoplastic; Dextrans; Female; Humans; Mitomycin; Mitomycins; Neoplas | 1985 |
[Topical application of mitomycin C conjugated with dextran (MMC-D): a high molecular weight derivative of mitomycin C].
Topics: Aged; Animals; Antibiotics, Antineoplastic; Dextrans; Female; Humans; Mitomycin; Mitomycins; Neoplas | 1985 |
[Fundamentals of thermochemotherapy of cancer].
Topics: Antineoplastic Agents; Benzaldehydes; Bleomycin; Cell Cycle; Cell Survival; Combined Modality Therap | 1987 |
[Fundamentals of thermochemotherapy of cancer].
Topics: Antineoplastic Agents; Benzaldehydes; Bleomycin; Cell Cycle; Cell Survival; Combined Modality Therap | 1987 |
[Application of immunotoxin in cancer therapy; its usefulness and problems in the future].
Topics: Antibodies, Monoclonal; Dextran Sulfate; Dextrans; Humans; Immunotoxins; In Vitro Techniques; Mitomy | 1989 |
[Application of immunotoxin in cancer therapy; its usefulness and problems in the future].
Topics: Antibodies, Monoclonal; Dextran Sulfate; Dextrans; Humans; Immunotoxins; In Vitro Techniques; Mitomy | 1989 |
Phase I trial of mitomycin C immunoconjugates cocktails in human malignancies.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Cytotoxicity, Immunologic; Dose-Re | 1989 |
Phase I trial of mitomycin C immunoconjugates cocktails in human malignancies.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Cytotoxicity, Immunologic; Dose-Re | 1989 |
[Basic and clinical study of adoptive immunotherapy using cytotoxic T lymphocyte (CTL) against cancers].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Agents; Breast Neoplasms; Combined Modality Therapy; Cytot | 1989 |
[Basic and clinical study of adoptive immunotherapy using cytotoxic T lymphocyte (CTL) against cancers].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Agents; Breast Neoplasms; Combined Modality Therapy; Cytot | 1989 |
Augmentation of the generation of lymphokine-activated killer cells after a single dose of mitomycin C in cancer patients.
Topics: Antigens, Differentiation; Antigens, Differentiation, T-Lymphocyte; CD4-Positive T-Lymphocytes; CD8 | 1989 |
Augmentation of the generation of lymphokine-activated killer cells after a single dose of mitomycin C in cancer patients.
Topics: Antigens, Differentiation; Antigens, Differentiation, T-Lymphocyte; CD4-Positive T-Lymphocytes; CD8 | 1989 |
[Arterial infusion method: its theory and clinical application--dosage and regimen].
Topics: Antineoplastic Agents; Bleomycin; Doxorubicin; Drug Administration Schedule; Fluorouracil; Humans; I | 1985 |
[Arterial infusion method: its theory and clinical application--dosage and regimen].
Topics: Antineoplastic Agents; Bleomycin; Doxorubicin; Drug Administration Schedule; Fluorouracil; Humans; I | 1985 |
Generation of human cytotoxic T lymphocytes against autologous solid tumors by autologous mixed lymphocyte tumor cell culture with T cell growth factor.
Topics: Animals; Antibodies, Monoclonal; Antigen-Antibody Reactions; Cells, Cultured; Cytotoxicity Tests, Im | 1985 |
Generation of human cytotoxic T lymphocytes against autologous solid tumors by autologous mixed lymphocyte tumor cell culture with T cell growth factor.
Topics: Animals; Antibodies, Monoclonal; Antigen-Antibody Reactions; Cells, Cultured; Cytotoxicity Tests, Im | 1985 |
Augmentation of the generation of OK-432 activated killer cells after a single dose of mitomycin C in cancer patients.
Topics: Biological Products; Humans; In Vitro Techniques; Injections, Intravenous; Killer Cells, Natural; Le | 1988 |
Augmentation of the generation of OK-432 activated killer cells after a single dose of mitomycin C in cancer patients.
Topics: Biological Products; Humans; In Vitro Techniques; Injections, Intravenous; Killer Cells, Natural; Le | 1988 |
[Tumor-targeted chemotherapy with lipid contrast medium and macro molecular anticancer agents theoretical considerations and clinical outcome].
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Biological Availability; Capillary Perm | 1985 |
[Tumor-targeted chemotherapy with lipid contrast medium and macro molecular anticancer agents theoretical considerations and clinical outcome].
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Biological Availability; Capillary Perm | 1985 |
[Basic study of anti-cancer agents suspended in lipiodol].
Topics: Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations; Doxorubicin; Fluorourac | 1986 |
[Basic study of anti-cancer agents suspended in lipiodol].
Topics: Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations; Doxorubicin; Fluorourac | 1986 |
[Combination of selective intra-arterial infusion of an anticancer agent via the vascular access port with RF local hyperthermia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Hyperthermia, In | 1986 |
[Combination of selective intra-arterial infusion of an anticancer agent via the vascular access port with RF local hyperthermia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Hyperthermia, In | 1986 |
[In vitro phase II-III study by clonogenic assay: the combined effects of mitomycin C with alpha-interferon].
Topics: Cell Division; Colony-Forming Units Assay; Drug Evaluation; Drug Synergism; Humans; Interferon Type | 1986 |
[In vitro phase II-III study by clonogenic assay: the combined effects of mitomycin C with alpha-interferon].
Topics: Cell Division; Colony-Forming Units Assay; Drug Evaluation; Drug Synergism; Humans; Interferon Type | 1986 |
Differing contribution of various effector cells in the elimination of syngeneic or allogeneic cells.
Topics: Animals; Antibodies, Neoplasm; Antibody Specificity; Cells, Cultured; Cytotoxicity, Immunologic; Fib | 1986 |
Differing contribution of various effector cells in the elimination of syngeneic or allogeneic cells.
Topics: Animals; Antibodies, Neoplasm; Antibody Specificity; Cells, Cultured; Cytotoxicity, Immunologic; Fib | 1986 |
[Intra-arterial embolization of microcapsulated mitomycin C in the treatment of advanced carcinoma].
Topics: Adult; Aged; Capsules; Embolization, Therapeutic; Female; Gallbladder Neoplasms; Humans; Injections, | 1986 |
[Intra-arterial embolization of microcapsulated mitomycin C in the treatment of advanced carcinoma].
Topics: Adult; Aged; Capsules; Embolization, Therapeutic; Female; Gallbladder Neoplasms; Humans; Injections, | 1986 |
High-dose mitomycin-C with autologous bone marrow transplantation in patients with refractory malignancies. Influence of dose schedule on pharmacokinetics and nonhematopoietic toxicities.
Topics: Adult; Bone Marrow Transplantation; Chemical and Drug Induced Liver Injury; Colitis, Ulcerative; Com | 1986 |
High-dose mitomycin-C with autologous bone marrow transplantation in patients with refractory malignancies. Influence of dose schedule on pharmacokinetics and nonhematopoietic toxicities.
Topics: Adult; Bone Marrow Transplantation; Chemical and Drug Induced Liver Injury; Colitis, Ulcerative; Com | 1986 |
In vitro sensitivity of normal and hereditary retinoblastoma fibroblasts to DNA-damaging agents.
Topics: Cells, Cultured; Dactinomycin; DNA; DNA Damage; DNA Repair; Eye Neoplasms; Fibroblasts; Gamma Rays; | 1986 |
In vitro sensitivity of normal and hereditary retinoblastoma fibroblasts to DNA-damaging agents.
Topics: Cells, Cultured; Dactinomycin; DNA; DNA Damage; DNA Repair; Eye Neoplasms; Fibroblasts; Gamma Rays; | 1986 |
[Clinical study of combination chemotherapy with cisplatin (CDDP), continuously infused 5-fluorouracil (5-Fu) and mitomycin C (MMC) (PFM therapy)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans | 1986 |
[Clinical study of combination chemotherapy with cisplatin (CDDP), continuously infused 5-fluorouracil (5-Fu) and mitomycin C (MMC) (PFM therapy)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans | 1986 |
Absence of interaction between furosemide and mitomycin C.
Topics: Adult; Drug Interactions; Female; Furosemide; Humans; Kidney; Kinetics; Male; Middle Aged; Mitomycin | 1987 |
Absence of interaction between furosemide and mitomycin C.
Topics: Adult; Drug Interactions; Female; Furosemide; Humans; Kidney; Kinetics; Male; Middle Aged; Mitomycin | 1987 |
[A new anti-cancer agent K-18 (conjugate of human IgG and melphalan). (II). Its inhibitory effects on in vitro DNA synthesis of human tumor cells].
Topics: Antineoplastic Agents; Cells, Cultured; DNA, Neoplasm; Doxorubicin; Humans; Immunoglobulin G; Melpha | 1986 |
[A new anti-cancer agent K-18 (conjugate of human IgG and melphalan). (II). Its inhibitory effects on in vitro DNA synthesis of human tumor cells].
Topics: Antineoplastic Agents; Cells, Cultured; DNA, Neoplasm; Doxorubicin; Humans; Immunoglobulin G; Melpha | 1986 |
Comparative studies on in vitro human tumor clonogenic assay (HTCA) and in vivo nude mouse-isotope assay (NM-IA).
Topics: Animals; Antineoplastic Agents; Colony-Forming Units Assay; Cyclophosphamide; Doxorubicin; Fluoroura | 1987 |
Comparative studies on in vitro human tumor clonogenic assay (HTCA) and in vivo nude mouse-isotope assay (NM-IA).
Topics: Animals; Antineoplastic Agents; Colony-Forming Units Assay; Cyclophosphamide; Doxorubicin; Fluoroura | 1987 |
Therapeutic attack of hypoxic cells of solid tumors: presidential address.
Topics: Animals; Humans; Hypoxia; Mitomycin; Mitomycins; Neoplasms; Neoplasms, Experimental | 1988 |
Therapeutic attack of hypoxic cells of solid tumors: presidential address.
Topics: Animals; Humans; Hypoxia; Mitomycin; Mitomycins; Neoplasms; Neoplasms, Experimental | 1988 |
Mitomycin C-induced renal toxicity, a dose-dependent side effect?
Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Hemolysis; Hemolytic-Uremic Syndrome; Humans; | 1987 |
Mitomycin C-induced renal toxicity, a dose-dependent side effect?
Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Hemolysis; Hemolytic-Uremic Syndrome; Humans; | 1987 |
The pharmacokinetic plasma profile of mitomycin C, measured after sequential intermittent intravenous administration.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Injections, Intravenous | 1988 |
The pharmacokinetic plasma profile of mitomycin C, measured after sequential intermittent intravenous administration.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Injections, Intravenous | 1988 |
[Effect of intra-thoracic administration of an immune modulator (OK-432) with anti-cancer drugs (ADR and MMC)].
Topics: Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Products; D | 1988 |
[Effect of intra-thoracic administration of an immune modulator (OK-432) with anti-cancer drugs (ADR and MMC)].
Topics: Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Products; D | 1988 |
A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxor | 1988 |
A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxor | 1988 |
Relationship between the antioxidant enzyme DT-diaphorase and tumor response to mitomycin C treatment.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Line; Humans; Mice; Mice, Nude; Mitomycin; M | 1988 |
Relationship between the antioxidant enzyme DT-diaphorase and tumor response to mitomycin C treatment.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Line; Humans; Mice; Mice, Nude; Mitomycin; M | 1988 |
Effect of a hepatic activation system on the antiproliferative activity of hexamethylmelamine against human tumor cell lines.
Topics: Altretamine; Animals; Cell Division; Cell Line; Cyclophosphamide; Humans; Male; Microsomes, Liver; M | 1985 |
Effect of a hepatic activation system on the antiproliferative activity of hexamethylmelamine against human tumor cell lines.
Topics: Altretamine; Animals; Cell Division; Cell Line; Cyclophosphamide; Humans; Male; Microsomes, Liver; M | 1985 |
Phase I study of hepatic arterial degradable starch microspheres and mitomycin.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Evaluation; Female; Hepatic Artery; Humans; Infu | 1985 |
Phase I study of hepatic arterial degradable starch microspheres and mitomycin.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Evaluation; Female; Hepatic Artery; Humans; Infu | 1985 |
The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymp
Topics: Humans; Interleukin-2; Killer Cells, Natural; Lymphocyte Activation; Lymphocytes; Mitomycin; Mitomyc | 1985 |
The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymp
Topics: Humans; Interleukin-2; Killer Cells, Natural; Lymphocyte Activation; Lymphocytes; Mitomycin; Mitomyc | 1985 |
A bioassay to measure cytotoxicity of plasma from patients treated with mitomycin C.
Topics: Animals; Biological Assay; Cell Survival; Cells, Cultured; Chromatography, High Pressure Liquid; Cri | 1985 |
A bioassay to measure cytotoxicity of plasma from patients treated with mitomycin C.
Topics: Animals; Biological Assay; Cell Survival; Cells, Cultured; Chromatography, High Pressure Liquid; Cri | 1985 |
[Total-body hyperthermia and combined anticancer chemotherapy].
Topics: Angiotensin II; Antineoplastic Agents; Body Temperature; Cisplatin; Combined Modality Therapy; Doxor | 1985 |
[Total-body hyperthermia and combined anticancer chemotherapy].
Topics: Angiotensin II; Antineoplastic Agents; Body Temperature; Cisplatin; Combined Modality Therapy; Doxor | 1985 |
An implantable vascular access device for superselective administration of anticancer drugs.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Hot Temperature | 1985 |
An implantable vascular access device for superselective administration of anticancer drugs.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Hot Temperature | 1985 |
[A clinical trial of a new mitomycin C derivative, KW-2083 (7-N-(p-hydroxyphenyl)-mitomycin C)].
Topics: Adult; Aged; Animals; Antibiotics, Antineoplastic; Biliary Tract Neoplasms; Colonic Neoplasms; Colon | 1985 |
[A clinical trial of a new mitomycin C derivative, KW-2083 (7-N-(p-hydroxyphenyl)-mitomycin C)].
Topics: Adult; Aged; Animals; Antibiotics, Antineoplastic; Biliary Tract Neoplasms; Colonic Neoplasms; Colon | 1985 |